• SHOP
  • COMBOS
  • TESTIMONIALS
  • CART
  • INGREDIENTS
    • 2-DEOXY-D-GLUCOSE (2DG)
    • ACACIA CYANOPHYLLA FLOWER
    • ACORI GRAMINEI RHIZOMA
    • AEGLE MARMELOS CORREA
    • AGARICUS BLAZEI
    • AGED GARLIC EXTRACT
    • AFRAMOMUM MELEGUETA
    • ALOE ARBORESCENS
    • ALBIZIA
    • ALPINIA OFFICINARUM
    • ALTERNANTHERA SESSILIS
    • AMERICAN GINSENG
    • AMYGDALIN
    • ANACYCLUS PYRETHRUM
    • ANGELICA ARCHANGELICA
    • ANGELICA SINENSIS
    • ANTRODIA
    • ARTICHOKE LEAF
    • ARTOCARPIN
    • AJUGA TURKESTANICA
    • ASHWAGANDHA
    • ASPALATHIN
    • ASTRAGALUS COMPLANATUS
    • AVENA SATIVA
    • BACOPA MONNIERI
    • BAVACHIN
    • BEE POLLEN
    • BETULINIC ACID
    • BOSWELLIC ACID
    • BREVILIN A
    • CAMPESTEROL
    • CAPSAICIN
    • CARCININE
    • CASTICIN
    • CHRYSIN
    • CIANIDANOL
    • CINNAMOMUM ZEYLANICUM
    • CITRULLUS COLOCYNTHIS
    • CITRUS RETICULATA PEEL
    • CODONOPSIS
    • CONJUGATED LINOLEIC ACID
    • COSTUNOLIDE
    • CYANIDIN
    • CUCURBITACIN D
    • DAIDZEIN
    • DECURSIN
    • DELPHINIDIN
    • DIGITALIS PURPREA (DIGOXIN)
    • DIOSMIN
    • Ecklonia Cava
    • Ellagic Acid
    • EMBELIN
    • ERIODICTYOL
    • GALLIC ACID
    • GLYCITEIN
    • GLYCYRRHIZIN
    • HYPERFORIN
    • ICARIIN
    • ISORHAMNETIN
    • ISOORIENTIN
    • ISOVITEXIN
    • JACEOSIDIN
    • KAEMPFEROL
    • KIGELIA AFRICANA
    • KURARINONE
    • LEMON BALM
    • LICORICIDIN
    • LIPOIC ACID
    • LUPEOL
    • MAGNOLOL
    • MENAQUINONE 4
    • MULBERRY LEAF
    • NARINGENIN
    • NOBILETIN
    • OLEACEIN
    • OLEANOLIC ACID
    • OLIVE OIL
    • ORIDONIN
    • PARTHENOLIDE
    • PHLOROGLUCINOL
    • PHLORIZIN
    • PICEATANNOL
    • PRISTIMERIN
    • PROANTHOCYANIDINS
    • PROCYANIDIN B3
    • PSEUDOLARIC ACID B
    • PTEROSTILBENE
    • RUTIN
    • SOLIDAGO VIRGAUREA
    • TANGERETIN
    • TARAXASTEROL
    • TRICHOSTATIN A
    • WEDELOLACTONE
    • WOGONIN
    • YERBA MATE
  • ABOUT
  • SCIENTIFIC STUDIES
    • ADAPTOGENS
    • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
    • ADDICTION & THE BRAIN
    • ADDICTION & STRESS
    • ADDICTION WITHDRAWAL
    • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
    • ADIPOCYTE DIFFERENTIATION
    • ADROPIN
    • ALLERGIES & CYTOKINES
    • ALDOSTERONE & OBESITY/HYPERTENSION
    • ALZHEIMER’S, DEMENTIA, PARKINSON’S
    • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
    • ADVANCED GLYCATION END PRODUCTS (AGES)
    • ADDICTION TREATMENT
    • ADDICTION & DOPAMINE
    • AMPK
    • ANTI AGING
    • ANTIAGING EFFECTS OF COFFEE
    • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
    • ANTI-APOPTOTIC PATHWAYS
    • ANTI ATHEROGENIC
    • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
    • ANTI CARIOGENIC (Protecting From Tooth Decay)
    • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
    • ANTI GLYCATIVE
    • ANTI GLYCATION AGENTS
    • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
    • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
    • ANTI WRINKLE AGENTS
    • ANXIOGENIC
    • ANXIOLYTIC
    • APOPTOSIS
    • APOPTOSIS IN 3T3-L1
    • AUTOPHAGY
    • BCL-2
    • BCL-W
    • BCL-XL
    • BDNF
    • BECLIN-1 & AUTOPHAGY
    • BH3 MIMETICS
    • BIM aka BCL2L11
    • BIOMIMETIC HYDROXYAPATITE
    • BMI-1
    • BPA & OBESITY
    • BRASSINOSTEROIDS
    • CALORIE RESTRICTION
    • CALORIE RESTRICTION & LIFESPAN EXTENSION
    • CARBAMYLATION
    • CARBONYL SCAVENGER
    • CARBONYL STRESS
    • CARDIOPROTECTIVE AGENTS
    • CARDIAC GLYCOSIDES
    • CATALASE
    • CELL CYCLE ARREST
    • CENTENARIANS
    • CDK5
    • CHOLESTEROL EFFLUX
    • COGNITIVE ENHANCEMENT
    • COLD SHOCK PROTEINS
    • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
    • CONDITIONED PLACE PREFERENCE
    • CORTICOTROPIN RELEASING FACTOR
    • COSMECEUTICAL
    • CRYOTHERAPY
    • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
    • CYP2E1
    • CYTOKINES IN PAIN, INFLAMMATION & AGING
    • DAF-16
    • DEPERSONALIZATION
    • DIABETES & CANCER
    • DIHYDROTESTOSTERONE (DHT)
    • DNA METHYLATION & AGING
    • DNA REPAIR
    • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
    • DRY FASTING AND FLUID RESTRICTION FASTING
    • DYNORPHIN
    • ELLAGITANNINS
    • ENDOCRINE DISRUPTING CHEMICALS
    • ENLARGED HEART AND CARDIOMEGALY
    • EPIGENETIC ALTERATIONS
    • EPIGENETIC MODIFIERS
    • EPINEPHRINE
    • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
    • EXCITOXICITY & THE BRAIN
    • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
    • EXTRACELLULAR MICROVESICLES
    • EXTENDS LIFESPAN
    • EXTINCTION TRAINING
    • FASTING & THE BRAIN
    • FASTING & CANCER
    • FASTING MIMICKING DIET
    • FEAR EXTINCTION
    • FGF21
    • FLAVONES
    • GABA (γ-AMINOBUTYRIC ACID)
    • GALLOTANNINS
    • GLUCONEOGENESIS
    • GLUCOCORTICOID RECEPTOR ACTIVATION
    • GLUTAMATE & BRAIN
    • GLYCATION
    • GUT BRAIN AXIS
    • GYPENOSIDE
    • KLOTHO
    • K OPIOD RECEPTOR & ADDICTION
    • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
    • FGF21
    • FOXO3
    • FOXO4
    • HALLMARKS OF AGING
    • HAIR GROWTH
    • HAIR REGENERATION
    • HAIR REPIGMENTATION
    • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
    • HMGB1
    • HORMESIS
    • HPA AXIS
    • HSP70, THE ANTI-AGING PROTEIN
    • HSP90 INHIBITORS
    • HYPERGLYCEMIA
    • HYPERALGESIA
    • HYPERINSULINEMIA
    • HYPOTHALAMIC PITUITARY ADRENAL HPA AXIS
    • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
    • HYPOCRETIN OREXIN
    • IKK
    • IL-6/STAT3
    • IRISIN
    • ISOFLAVONES
    • IMMUNOSENESCENCE
    • INHIBITION OF ADVANCED GLYCATION END PRODUCTS
    • INCREASE PROTEIN SYNTHESIS
    • INCREASES SPERMATOGENESIS
    • INFECTOBESITY
    • INFLAMMATION & ANXIETY
    • INFLAMMATION & CANCER
    • INFLAMMATION & DEPRESSION
    • INFLAMMATION & OBESITY
    • INFLAMMAGING
    • INHIBITION OF RENAL GLUCOSE REABSORPTION
    • INSULIN & AGING
    • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
    • INSULIN & MTOR
    • INSULIN & OBESITY
    • INSULIN OXIDATIVE STRESS
    • INTERMITTENT FASTING
    • JAK INHIBITION ALLEVIATES SASP
    • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
    • KETONE BODIES
    • KETOGENIC DIET
    • LACTOBACILLUS REUTERI
    • LACTOFERRIN
    • LEYDIG CELL STEROIDOGENESIS
    • LIFESPAN EXTENSION
    • LIVER REGENERATION
    • LIPOLYTIC AGENTS
    • LIPID DROPLETS
    • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
    • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
    • MATRIX METALLOPROTEINASES (MMPs)
    • MCL-1
    • MDM2 INHIBITION AS SASP INHIBITOR
    • MEDICINAL MUSHROOMS
    • MEDITERRANEAN DIET
    • METABOLIC REPROGRAMMING
    • METABOLIC SYNDROME
    • METHIONINE RESTRICTION
    • MITOCHONDRIAL UNCOUPLING
    • MONKEYPOX
    • MSG (MONOSOSODIUM GLUTAMATE)
    • MUSCLE FORCE PRODUCTION
    • MUSCLE ATROPHY (PREVENTING)
    • MYOGENESIS
    • MYOSTATIN INHIBITION
    • MYOSTATIN INHIBITION PRESERVES MUSCLE
    • mTORC2
    • mTOR: THE RAPID AGING PATHWAY
    • NATURAL ANTICOAGULANTS
    • NATURAL AROMATASE INHIBITORS
    • NEUROGENESIS (GROWING NEW BRAIN CELLS)
    • NEUROCHEMISTRY OF ADDICTION
    • NEUROPLASTICITY
    • NEUROINFLAMMATION
    • NEUROPROTECTIVE AGENTS
    • NEUTRALIZING OXIDATIVE STRESS WITH MEDICINAL PLANTS
    • NMDA & ANXIETY & DEPRESSION
    • NMDA RECEPTOR & FEAR
    • NON OPIOD ANALGESICS
    • NOOTROPICS
    • NORADRENERGIC
    • NOREPINEPHRINE
    • NRF2: MASTER REGULATOR OF THE AGING PROCESS
    • NF-KB
    • NUTRACEUTICAL
    • OBESOGENS
    • ONCOGENE ACTIVATION INDUCED SENESCENCE
    • ORGANOTINS
    • OVERNUTRITION
    • OXIDATIVE STRESS & AGING
    • P16INK4A
    • P38MAPK
    • P53: TUMOR SUPRESSOR
    • PERIODONTITIS
    • PHOSPHATIDYLINOSITOL 3 KINASE
    • PHYTOCHEMICALS
    • PHYTOSTEROLS
    • PHYTOSTANOLS
    • PHYTOECDYSTEROIDS
    • PROANTHOCYANIDINS
    • PROTEIN CARBONYLATION
    • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
    • POLYPHENOLS AS COVID-19 TREATMENT & PREVENTION
    • PPARY2
    • PREMATURE SENESCENCE
    • PREVENTING SKIN AGING
    • PUFAS
    • PURGATIVES
    • RADIATION EXTRACT
    • RAPAMYCIN (MTOR INHIBITION)
    • RED WINE
    • RENAL (KIDNEY) PROTECTIVE AGENTS
    • REMINERALIZATION OF TEETH
    • REMYELINATION
    • REPAIR OF DNA BREAKS “DOUBLE STRAND”
    • RESTORE INSULIN SENSITIVITY
    • REVERSAL OF OBESITY
    • SASP & ADIPOSE TISSUE
    • SEX HORMONE BINDING GLOBULIN
    • SENESCENT CELLS, SASP & SENOLYTICS
    • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
    • SGLT2 INHIBITORS
    • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
    • SHBG
    • SIRT1
    • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
    • SKIN ELASTICITY
    • SKIN PHOTOAGING (Preventing & Repairing)
    • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
    • SIRT1 & LONGEVITY
    • SMALLPOX
    • SUGAR & AGING
    • STAR PROTEIN
    • STAT3
    • STEM CELL EXHAUSTION
    • STEM CELL REGENERATION
    • STEM CELL THERAPY
    • STIMULATED LIPOLYSYS
    • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
    • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
    • STRESS & AGING
    • STRESS & THE BRAIN
    • TELOMERE SHORTENING & PREMATURE AGING
    • TIME RESTRICTED FEEDING
    • THROMBOLYTICS (PLANT BASED)
    • TRAUMATIC BRAIN INJURY (HEALING)
    • TRYPTOPHAN HYDROXYLASE 2
    • VISCERAL ADIPOSITY
    • XENOBIOTICS
    • XENOESTROGEN
  • HOME
  • CONTACT
  • TELEGRAM PORTAL
  • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
  • The Ultimate Dry Fasting Resource
  • MY ACCOUNT
  • RESET PASSWORD
0
blank
Mcl-1
January 31, 2020
blank
Senescence-associated beta-galactosidase (SA-β-gal or SABG)
February 10, 2020

blank

Neuroprotective effects of flavonoids and polyphenols

 

  1. A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders
  2. A bird’s-eye view of the multiple biochemical mechanisms that propel pathology of Alzheimer’s disease: recent advances and mechanistic perspectives on …
  3. A blueberry extract-supplemented diet rescues phenotypes in drosophila melanogaster models of parkinson disease
  4. A Comparative Study on the Phenolic Composition and Biological Activities of Morus alba L. Commercial Samples
  5. A Comparison of the Antioxidant Activity with the Total Phenolic and Total flavonoid contents of the Leaves and Stem-bark of Anogeissus leiocarpa (DC.) Guill& Pirr …
  6. A comprehensive database and analysis framework to incorporate multiscale data types and enable integrated analysis of bioactive polyphenols
  7. A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis
  8. A Current Understanding of Alzheimer’s Disease and the Prospects of Phytopharmacological Intervention as a Management Strategy
  9. A meta-analysis of tea drinking and risk of Parkinson’s disease
  10. A molecular approach in drug development for Alzheimer’s disease
  11. A Narrative Review of Lifestyle Factors Associated with Parkinson’s Disease Risk and Progression
  12. A Novel GSK3β Inhibitor Reduces Tau Pathology in Alzheimer’s Disease
  13. A Paradigm Shift to Prevent and Treat Alzheimer’s Disease: From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols
  14. A pharmacological appraisal of neuroprotective and neurorestorative flavonoids against Neurodegenerative diseases
  15. A review of antioxidant and pharmacological properties of phenolic compounds in Acacia confusa
  16. A Review of Antioxidants and Alzheimer
  17. A review of antioxidants and Alzheimer’s disease
  18. A review of genome mutation and Alzheimer’s disease
  19. A review on cholinesterase inhibitors for Alzheimer’s disease
  20. A Review on Current Strategies and Future Perspective in Respect to Alzheimer’s Disease Treatment
  21. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer’s and Parkinson’s diseases
  22. A Review on Medicinal Plants for Alzheimer’s disease
  23. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions
  24. A review on potential mechanisms of Terminalia chebula in Alzheimer’s disease
  25. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer’s disease
  26. A review on the beneficial effects of tea polyphenols on human health
  27. A review on the status of the phenolic compounds and antioxidant capacity of the flour: Effects of cereal processing
  28. A review–probable mechanism of action of curcumin for the treatment of Alzheimer disease (AD)
  29. A review: inflammatory process in Alzheimer’s disease, role of cytokines
  30. A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model
  31. A Study on the Role of Mimosa Pudica (Thottar Chinungi) on the Experimental Models of Parkinsonism (Nadukku Vatham)
  32. A synopsis on the linkage between age-related dementias and vascular disorders
  33. A systematic review on the role of natural products in modulating the pathways in Alzheimer’s disease
  34. Acacetin—A simple flavone exhibiting diverse pharmacological activities
  35. Accumulation of citrus flavanones in bovine milk following citrus pulp incorporation into the diet of dairy cows
  36. Acetyl-cholinesterase Inhibition by Extracts and Isolated Flavones from Linaria reflexa Desf. (Scrophulariaceae)
  37. Acetylated flavonoid Glycosides Potentiating NGF Action from Scoparia dulcis
  38. Activation of pro‐survival Akt and ERK1/2 signalling pathways underlie the anti‐apoptotic effects of flavanones in cortical neurons
  39. Acute effects of flavonoid-rich blueberry on cognitive and vascular function in healthy older adults
  40. Adult‐onset brain tumors and neurodegeneration: Are polyphenols protective?
  41. Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer’s disease
  42. Advances in multi-functional ligands and the need for metal-related pharmacology for the management of Alzheimer disease
  43. Advances in research on active constituents of Chinese materia medica in treatment of Alzheimer’s disease [J]
  44. Agathisflavone, a flavonoid derived from Poincianella pyramidalis (Tul.), enhances neuronal population and protects against glutamate excitotoxicity
  45. Age-related cognitive impairment as a sign of geriatric neurocardiovascular interactions: may polyphenols play a protective role?
  46. Aging risk factors and Parkinson’s disease: contrasting roles of common dietary constituents
  47. Alcohol Consumption in Predementia and dementia Syndromes
  48. Alcohol intake and risk of dementia
  49. Alcohol, wine and mental health: focus on dementia and stroke
  50. Alcoholic beverages and incidence of dementia: 34-year follow-up of the prospective population study of women in Göteborg
  51. Almond, hazelnut and walnut, three nuts for neuroprotection in Alzheimer’s disease: A neuropharmacological review of their bioactive constituents
  52. Alpha-secretase ADAM10 regulation: insights into Alzheimer’s disease treatment
  53. Alpha-Synuclein and synuceinopathies as related to Parkinson’s disease
  54. Alpha-synuclein oligomers—neurotoxic molecules in Parkinson’s disease and other Lewy body disorders
  55. Altered Micro-RNA Regulation and Neuroprotection Activity of Eremostachys labiosiformis in Alzheimer’s Disease Model
  56. Alzheimer’s and Parkinson’s Disease Novel Therapeutic Target: The Mitochondrial Pyruvate Carrier-Ligand Docking to Screen Natural Compounds Related to Classic …
  57. Alzheimer’s Dementia: Can It Be Prevented?
  58. Alzheimer’s disease (AD) genes: Enrichment in cancer genes and those related to comorbid conditions, risk factors (pollution and pathogens) or beneficial agents …
  59. Alzheimer’s Disease & Treatment
  60. Alzheimer’s Disease & Treatment
  61. Alzheimer’s Disease & Treatment
  62. Alzheimer’s Disease & Treatment, Vol. 1
  63. Alzheimer’s disease and antioxidant therapy: how long how far?
  64. Alzheimer’s disease and its current treatments; Is there a possibility for a cure
  65. Alzheimer’s Disease and Metal Contamination: Aspects on Genotoxicity
  66. Alzheimer’s disease and natural products: Future regimens emerging from nature
  67. Alzheimer’s disease and other Neurodegenerative disorders
  68. Alzheimer’s Disease and Oxidative Stress
  69. Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and …
  70. Alzheimer’s Disease and the Main Aspects-Literature Review
  71. Alzheimer’s DISEASE AND THE MICROBIOME
  72. Alzheimer’s disease as oligomeropathy
  73. Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
  74. Alzheimer’s Disease Theranostics
  75. Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention.
  76. Alzheimer’s Disease, Drosophila melanogaster and Polyphenols
  77. Alzheimer’s disease, neuroinflammation and the influence of different combinations of nutrients
  78. Alzheimer’s disease: A challenge in managing with certain medicinal plants-Areview
  79. Alzheimer’s disease: a journey from amyloid peptides and oxidative stress, to biomarker technologies and disease prevention strategies—gains from AIBL …
  80. Alzheimer’s Disease: An Approach for Non-Pharmacological Therapies
  81. Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools
  82. Alzheimer’s Disease: Early Diagnosis & Fundamental Therapeutics
  83. Alzheimer’s disease: from pathology to therapeutic approaches
  84. Alzheimer’s disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms
  85. Alzheimer’s disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the …
  86. Alzheimers Disease & Parkinsonism
  87. Ameliorating effect of ethanol leaf extract of Ficus hispida Linn. on amyloid beta Aβ (25-35) induced cognitive deficits and oxidative stress in Alzheimer’s mice
  88. Amelioration of 6-Hydroxydopamine-Lesion Induced Neurotoxicity by Different Extracts of Ocimum sanctum Leaves in Rodent Model of Parkinson’s Disease
  89. Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer’s type
  90. Amentoflavone Ameliorates Aβ1–42-Induced Memory Deficits and oxidative stress in Cellular and Rat Model
  91. Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson’s disease model mice through PI3K/Akt and ERK signaling pathways
  92. Amentoflavone suppresses amyloid β1–42 neurotoxicity in Alzheimer’s disease through the inhibition of pyroptosis
  93. AMP‐activated protein kinase: a potential player in Alzheimer’s disease
  94. Amyloid A-Beta Peptide: In-Cell Studies and Mechanism of Polyphenol-Based Inhibition to Aggregation
  95. Amyloid precursor protein‐mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer’s disease
  96. Amyloid β-Peptide (1–42)-Induced oxidative stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression
  97. Amyloid β-protein assembly as a therapeutic target of Alzheimer’s disease
  98. Amyloid‐β deposition in Alzheimer transgenic mice is associated with oxidative stress
  99. An alternative approach to drug discovery for Alzheimer’s disease dementia
  100. An Evaluation of Cholesterol-lowering Effect of Soy Protein and Isoflavones on Postmenopausal Women and Hypercholesterolemic Humans.
  101. An Overview of Parkinson’s Disease and Oxidative Stress: Herbal Scenario
  102. An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimer’s disease
  103. An overview on global trends in nanotechnological approaches for Alzheimer therapy
  104. An overview on potential neuroprotective compounds for management of Alzheimer’s disease
  105. An overview on therapeutics attenuating amyloid β level in Alzheimer’s disease: Targeting neurotransmission, inflammation, oxidative stress and enhanced …
  106. An update on plant-originated treatment for Alzheimer’s disease
  107. An updated review on Anti-Alzheimer’s herbal drugs
  108. Analgesic and acetylcholinesterase inhibition potential of polyphenols from Scolopia crenata (Flacourtiaceae): An endemic medicinal plant of India
  109. Analysis of amino acid and phenolic content in honey by UPLC-ESI-MS/MS
  110. Analysis of technological developments in the treatment of Alzheimer’s disease through patent documents
  111. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson’s Disease
  112. Anesthesia Implications of the Use of Essential Oils in Alzheimer’s Dementia
  113. Animal models of Parkinson’s disease: a gateway to therapeutics?
  114. Anthocyanins Potentially Contribute to Defense against Alzheimer’s Disease
  115. Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer’s type
  116. Anti-acetylcholinesterase and antioxidant activities and HPLC-MS analysis of polyphenol from extracts of Nelsonia canescens (Lam.) Spreng.
  117. Anti-adipogenic Effect of a Dietary flavonoid Fisetin in 3T3-L1 Cells
  118. Anti-aging and anti-aggregation properties of polyphenolic compounds in C. elegans
  119. Anti-Alzheimer potential of Green Moong Bean
  120. Anti-Alzheimer’s studies on β-sitosterol isolated from Polygonum hydropiper L.
  121. Anti-amnesic Effect of Leea indica Extract in Scopolamine-induced Amnesia of Alzheimer’s Type in Rats
  122. Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer’s β-amyloid fibrils in vitro
  123. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer’s disease
  124. Anti-amyloidogenic properties of some phenolic compounds
  125. Anti-Demential Effect of EGB 761 on dementia Induced Wistar Rats
  126. Anti-Inflammatory Agents in Parkinson’s Disease
  127. Anti-inflammatory and immune therapy for Alzheimer’s disease: current status and future directions
  128. Anti-inflammatory and immunomodulatory properties of dietary flavonoids
  129. Anti-inflammatory Effects of flavonoid Compounds on TNBS-induced Acute Colitis in Rats
  130. Anti-inflammatory effects of flavonoids in Neurodegenerative disorders
  131. Anti-inflammatory Effects of O-methylated Flavonoid
  132. Anti-inflammatory, anti-diabetic, and anti-Alzheimer’s effects of prenylated flavonoids from Okinawa propolis: an investigation by experimental and computational …
  133. Anti-inflammatory, immunomodulatory, and prebiotic properties of dietary flavonoids
  134. Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer’s disease
  135. Anti-Parkinson potential of silymarin: mechanistic insight and therapeutic standing
  136. Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models?
  137. Antiaging Interventions: An Insight into Polyphenols and Brain Aging
  138. Antiapoptotic role of Agaricus blazei extract in rodent model of Parkinson’s disease
  139. Antidementic activity of Brassica oleracea l. var. Italica (brassicaceae) flower on memory deficit in young male rats
  140. Antidepressant flavonoids and their relationship with oxidative stress
  141. Antihepatotoxic, nephroprotective, and antioxidant activities of phenolic compounds from Satureja macrostema leaves against carbon tetrachloride-induced hepatic …
  142. Antioxidant activity and total phenolic content of ethanolic extract of Caesalpinia bonducella seeds
  143. Antioxidant activity of selected phenols estimated by ABTS and FRAP methods.
  144. Antioxidant Activity of Wine Polyphenols for Alzheimer Prevention
  145. Antioxidant and anti‐inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental …
  146. Antioxidant and Anticholinesterase Activities of Macrosphyra Longistyla (DC) Hiern Relevant in the Management of Alzheimer’s Disease
  147. Antioxidant and Choline Esterase Inhibitory Activity of Phenolic Rich Extracts from Bombax ceiba L. Flowers.
  148. Antioxidant and neuroprotective Effects of Synthetic Curcumin Analogues and Natural Phenolics
  149. Antioxidant and neuroprotective properties of blueberry polyphenols: a critical review
  150. Antioxidant and pro-oxidant effects of polyphenolic compounds and structure-activity relationship evidence
  151. Antioxidant Capacity and Behavioral Relevance of a Polyphenolic Extract of Chrysanthellum americanum in a Rat Model of Irritable Bowel Syndrome
  152. Antioxidant Capacity is Decreased in Alzheimer’s Disease and Mild Cognitive Impairment Patients
  153. ANTIOXIDANT EFFECT OF flavonoids IN Neurodegenerative DISEASES.
  154. Antioxidant effect of flavonoids present in Euterpe oleracea Martius and Neurodegenerative diseases: A literature review
  155. Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach
  156. Antioxidant Nutraceuticals and Parkinson’s Disease
  157. Antioxidant phenolic constituents from Parthenocissus tricuspidata
  158. Antioxidant plant polyphenols and cognitive disorders
  159. ANTIOXIDANT PROPERTIES OF A Ginkgo biloba LEAF EXTRACT (EGb 761) IN ANIMAL MODELS OF Alzheimer’s AND Parkinson’s DISEASES.
  160. Antioxidant properties of Crocus sativus L. and its constituents and relevance to Neurodegenerative diseases; focus on Alzheimer’s and Parkinson’s disease
  161. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease
  162. Antioxidant therapy in Alzheimer’s disease: theory and practice
  163. Antioxidants and Alzheimer’s disease: from bench to bedside (and back again)
  164. Antioxidants and dementia risk: consideration through a cerebrovascular perspective
  165. Antioxidants as a potential therapy against age-related Neurodegenerative diseases: amyloid beta toxicity and Alzheimer’s disease
  166. Antioxidants in the Prevention and Treatment of Alzheimer’s Disease
  167. Antioxidants, diet, polyphenols and dementia
  168. Apolipoprotein ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity
  169. Apples and their products effect on neurodegeneration and Alzheimer’s disease
  170. Application of yeast to study the tau and amyloid-β abnormalities of Alzheimer’s disease
  171. Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
  172. Applying transcriptomic and proteomic knowledge to Parkinson’s disease drug discovery
  173. Approaches Based on Cholinergic Hypothesis and Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease
  174. Are polyphenols strong dietary agents against neurotoxicity and neurodegeneration?
  175. Arecanut (Areca catechu L) decreases Alzheimer’s disease symptoms: Compilation of research works
  176. Artemisia amygdalina Upregulates Nrf2 and Protects Neurons Against oxidative stress in Alzheimer Disease
  177. Asparagus cochinchinensis stimulates release of nerve growth factor and abrogates oxidative stress in the Tg2576 model for Alzheimer’s disease
  178. Assessment of anticholinesterase activities and antioxidant potentials of Anisomeles indica relevant to the treatment of Alzheimer’s disease
  179. Assessment of the effect of selected African plants on an in vitro model of Parkinson’s disease
  180. association of tea consumption with risk of Alzheimer’s disease and anti-beta-amyloid effects of tea
  181. ATR-IR study of the mechanism of aluminum chloride induced Alzheimer’s disease; curative and protective effect of Lipidium sativum water extract on …
  182. Attention-deficit/hyperactivity disorder–unifying mechanism involving antioxidant therapy: Phenolics, reactive oxygen species, and oxidative stress
  183. Attenuation of iNOS and COX2 by blueberry polyphenols is mediated through the suppression of NF-κB activation
  184. Auraptene Mitigates Parkinson’s Disease-Like Behavior by Protecting Inhibition of Mitochondrial Respiration and Scavenging Reactive Oxygen Species
  185. Autophagy in Alzheimer’s disease and promising modulatory effects of herbal medicine
  186. Autophagy, polyphenols and healthy ageing
  187. Aβ propagation and strains: implications for the phenotypic diversity in Alzheimer’s disease
  188. BACE inhibitors as potential therapeutics for Alzheimer’s disease
  189. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer’s disease
  190. Baicalein reduces β‐amyloid and promotes nonamyloidogenic amyloid precursor protein processing in an Alzheimer’s disease transgenic mouse model
  191. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease
  192. Behavioral and neurochemical alterations induced by vanillin in a mouse model of Alzheimer’s disease
  193. Beneficial effect of flavone derivatives on Aβ-induced memory deficit is mediated by peroxisome proliferator-activated receptor γ coactivator 1α: a comparative study
  194. Beneficial effect of the flavonoid luteolin on neuroinflammation
  195. Beneficial effects of flavonoids against Parkinson’s disease
  196. Beneficial Effects of flavonoids on Neurological Disorders
  197. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson’s disease: the role of glia and NRf2 regulation
  198. Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration
  199. Beneficial effects of phenolic compounds from fruit and vegetables in Neurodegenerative diseases
  200. Beneficial effects of polyphenols on chronic diseases and ageing
  201. Beneficial properties of natural phenols: highlight on protection against pathological conditions associated with amyloid aggregation
  202. Benefits from dietary polyphenols for brain aging and Alzheimer’s disease
  203. Berry phenolics and their antioxidant activity
  204. Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer’s disease
  205. Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain
  206. Biflavonoids as potential small molecule therapeutics for Alzheimer’s disease
  207. Bioactive composition and promising health benefits of natural food flavors and colorants: potential beyond their basic functions
  208. Bioactive flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers-Implications for Parkinson’s Disease
  209. Bioactivity of olive oil phenols in neuroprotection
  210. Bioanalytical Approach to the Interaction of Novel sym-Triazine Derivatives with Alzheimer’s Disease Biomarkers
  211. Bioanalytical Approaches to Investigate Antioxidant Molecules and Nucleic Acid-Protein Interactions in Alzheimer’s Disease
  212. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts
  213. Bioavailability and pharmaco-therapeutic potential of luteolin in overcoming Alzheimer’s disease
  214. Bioavailability of dietary polyphenols: Factors contributing to their clinical application in CNS diseases
  215. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update
  216. Biochanin-A ameliorates behavioural and neurochemical derangements in cognitive-deficit mice for the betterment of Alzheimer’s disease
  217. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis
  218. Biological reactivity of polyphenolic− glutathione conjugates
  219. Biopharmaceutical Monotargeting versus ‘Universal Targeting’of Late-Onset Alzheimer’s Disease Using Mixtures of Pleiotropic Natural Compounds
  220. Biophenols pharmacology against the amyloidogenic activity in Alzheimer’s disease
  221. Biophenols: Enzymes (β-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.)
  222. Biophysical characteristics of proteins and living cells exposed to the green tea polyphenol epigallocatechin-3-gallate (EGCg): review of recent advances from …
  223. Bioprocessing Strategies to Enhance L-DOPA and Phenolic Bioactives in the Fava Bean (Vicia Faba)
  224. Biosynthesized metal nanoparticles as potential Alzheimer’s disease therapeutics
  225. Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils
  226. Blanching alters the phenolic constituents and in vitro antioxidant and anticholinesterases properties of fireweed (Crassocephalum crepidioides)
  227. Blueberry polyhphenols and neuroprotection
  228. Blueberry polyphenols and neuroprotection
  229. Botanical phenolics and brain health
  230. Botanics: a potential source of new therapies for Alzheimer’s disease
  231. Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer’s disease
  232. Brain food for Alzheimer-free ageing: focus on herbal medicines
  233. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer’s disease
  234. Brain iron accumulation in Parkinson’s disease: An investigation of genes related to iron metabolism and homeostasis and dietary behavior data in a case …
  235. Brain iron metabolism dysfunction in Parkinson’s disease
  236. Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson’s disease
  237. C0550 Neuroinflammation in Alzheimer’s Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals
  238. Caffeic acid attenuates oxidative stress, learning and memory deficit in intra-cerebroventricular streptozotocin induced experimental dementia in rats
  239. Can co-activation of Nrf2 and neurotrophic signaling pathway slow Alzheimer’s disease?
  240. Can consuming flavonoids restore old microglia to their youthful state?
  241. Can we prevent Parkinson’s disease
  242. Cannabis Flavonoids—Antioxidant & Anti-Inflammatory Benefits
  243. Carbohydrates and Glycomimetics in Alzheimer’s Disease Therapeutics and Diagnosis
  244. Carbon nanomaterials and amyloid beta interactions: Possible potentials in the detection and treatment of Alzheimer’s disease
  245. Catechin polyphenols: neurodegeneration and neuroprotection in Neurodegenerative diseases
  246. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG)
  247. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for Neurodegenerative diseases
  248. Cellular and molecular aspects of Parkinson treatment: future therapeutic perspectives
  249. Cellular and molecular mechanisms of antioxidants in Parkinson’s disease
  250. Cellular phenotypes as inflammatory mediators in Parkinson’s disease: interventional targets and role of natural products
  251. Cerebral area differential redox response of neonatal rats to selenite-induced oxidative stress and to concurrent administration of highbush blueberry leaf polyphenols
  252. Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer’s …
  253. Challenges for research on polyphenols from foods in Alzheimer’s disease: bioavailability, metabolism, and cellular and molecular mechanisms
  254. Champagne wine polyphenols protect primary cortical neurons against peroxynitrite-induced injury
  255. Changing paradigm from one target one ligand towards multi-target directed ligand design for key drug targets of Alzheimer disease: an important role of in silico …
  256. Characterization of Copper Interactions with Alzheimer Amyloid β Peptides: Identification of an Attomolar‐Affinity Copper Binding Site on Amyloid β1‐42
  257. Characterization of Copper Interactions with Alzheimer Amyloid β Peptides: Identification of an Attomolar‐Affinity Copper Binding Site on Amyloid β1‐42
  258. Characterization of neurotoxic effects of NMDA and the novel neuroprotection by phytopolyphenols in mice.
  259. Characterization of phenolic compounds using UPLC–HRMS and HPLC–DAD and anti-cholinesterase and anti-oxidant activities of Trifolium repens L. leaves
  260. CHARACTERIZATION OF THE neuroprotective ACTIVITY OF THE polyphenol (-)-EPIGALLOCATECHIN-3-GALLATE IN THE BRAIN
  261. Charnoly body as a novel biomarker of nutritional stress in Alzheimer’s Disease
  262. Chemical fingerprint of Bacopa monnieri L. and Rosmarinus officinalis L. and their neuroprotective activity against Alzheimer’s disease in rat model’s putative …
  263. Chemical structures, bioactivities and molecular mechanisms of citrus polymethoxyflavones
  264. Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease
  265. Chocolate and the brain: neurobiological impact of cocoa flavanols on cognition and behavior
  266. Chocolate/Cocoa Polyphenols and Oxidative Stress
  267. Cholinesterase inhibitors as Alzheimer’s therapeutics
  268. Chroman-like cyclic prenylflavonoids promote neuronal differentiation and neurite outgrowth and are neuroprotective
  269. Chronic dietary supplementation of 4% figs on the modification of oxidative stress in Alzheimer’s disease transgenic mouse model
  270. Chronic Hypoxia Alters mRNA Expression of the Genes Related to Alzheimer’s Disease in Primary Neuronal Cells
  271. Chronic neuroinflammation in Alzheimer’s disease: new perspectives on animal models and promising candidate drugs
  272. Chronic treatment with resveratrol, a natural polyphenol found in grapes, alleviates oxidative stress and apoptotic cell death in ovariectomized female rats subjected to …
  273. Cinnamon, a promising prospect towards Alzheimer’s disease
  274. Citrus Fruit Polyphenols and Flavonoids: Applications to Psychiatric Disorders
  275. Clinical benefit and preservation of flavonols in dark chocolate manufacturing
  276. Clinical Development of a Novel Parkinsonian Drug in USA
  277. Cocoa and dark chocolate polyphenols: from biology to clinical applications
  278. Cocoa flavanols, exercise and the brain
  279. Cocoa Powder Triggers neuroprotective and Preventive Effects in a Human Alzheimer 0 s Disease Model by Modulating BDNF Signaling Pathway
  280. Cocoa powder triggers neuroprotective and preventive effects in a human Alzheimer’s disease model by modulating BDNF signaling pathway
  281. Coffee phenolic phytochemicals and kaempferol protect against oxidative damage of neuronal cells and memory impairments
  282. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review
  283. Cognitive Function and Consumption of Fruit and Vegetable Polyphenols in a Young Population: Is There a Relationship?
  284. Cognitive stimulation with leisure activities for prevention of cognitive decline and dementia: The aktiva study
  285. Cognitive-enhancing effect of quercetin in a rat model of Parkinson’s disease induced by 6-hydroxydopamine
  286. Combating oxidative stress disorders with citrus flavonoid: Naringenin
  287. Combination of EPA with carotenoids and polyphenol synergistically attenuated the transformation of microglia to M1 phenotype via inhibition of NF-κB
  288. Commentary: The flavonoid Baicalein Rescues Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer’s Disease
  289. Comparative analysis of total phenolic and total flavonoid contents, rutin, tannins and antioxidant capacity in Apiaceae and Lamiaceae families
  290. Comparative antioxidant activity of twenty traditional Indian medicinal plants and its correlation with total flavonoid and phenolic content
  291. Comparative evaluation of Helichrysi flos herbal extracts as dietary sources of plant polyphenols, and macro-and microelements
  292. Comparative evaluation of the antioxidant and anti-Alzheimer’s disease potential of coumestrol and puerarol isolated from pueraria lobata using molecular modeling …
  293. Comparative study on the inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer’s disease and some pro-oxidant induced oxidative …
  294. Comparison of protective effects of four polyphenols on neuropathology and behavior of APP/PS1-21 transgenic mice, a model of Alzheimer’s disease
  295. Comparison of Three Amyloid Assembly Inhibitors: The Sugar scyllo-Inositol, the polyphenol Epigallocatechin Gallate, and the Molecular Tweezer CLR01
  296. Complementary Therapies for Parkinson’s Disease: What’s Promoted, Rationale, Potential Risks and Benefits
  297. Compositional Changes in Anthocyanins, Flavonols, and Ellagitannins in Processed Blackberries
  298. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies
  299. Computational approaches to the investigation of proteins involved in Parkinson’s Disease
  300. Computational modeling of multi-target-directed inhibitors against Alzheimer’s disease
  301. Computer-aided structure-based design of multitarget leads for Alzheimer’s disease
  302. Conjugates of catecholamines with cysteine and GSH in Parkinson’s disease: possible mechanisms of formation involving reactive oxygen species
  303. Conservative iron chelation for Neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis
  304. Considerations for the use of polyphenols as therapies in Neurodegenerative diseases
  305. Consumption of anthocyanin-rich cherry juice for 12 weeks improves memory and cognition in older adults with mild-to-moderate dementia
  306. Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer’s disease
  307. Consumption of polyphenol plants may slow aging and associated diseases
  308. Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for …
  309. Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for …
  310. Copper-Catalyzed Oxidative Esterification of 2-Carbonyl Substituted Phenols with Alcohols
  311. Correlation between the polyphenol content and antioxidant effect of Cynara scolymus L. mother tincture
  312. Critical Evaluation of Current Alzheimer′ s Drug Discovery (2018-19) & Futuristic Alzheimer drug model approach
  313. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease
  314. Curcumin and Apigenin–novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease
  315. Curcumin and Its Nanoformulations as Therapeutic for Alzheimer’s Disease
  316. Curcumin exposure induces expression of the Parkinson’s disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells
  317. Curcumin has potent anti‐amyloidogenic effects for Alzheimer’s β‐amyloid fibrils in vitro
  318. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models
  319. Curcumin prevents and ameliorates biochemical and behavioral toxicities of MPTP in C57Bl/6J mice: its potential use in preventing and treating parkinsonism
  320. Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits α-synuclein oligomer formation: relevance to Parkinson’s disease
  321. Current Alzheimer’s management with berries fruits therapy
  322. CURRENT Alzheimer’s MANAGEMENT WITH DIETARY SEEDS THERAPY
  323. Current and emerging pharmacological targets for the treatment of Alzheimer’s disease
  324. Current and emerging therapeutic targets of Alzheimer’s disease for the design of multi-target directed ligands
  325. Current and investigational drugs for treatment of Alzheimer’s disease
  326. Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer’s disease
  327. Current evidence on the effect of dietary polyphenols intake on chronic diseases
  328. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson’s disease
  329. Current perspectives and mechanisms of relationship between intestinal microbiota dysfunction and dementia: a review
  330. Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease
  331. Current status of metals as therapeutic targets in Alzheimer’s disease
  332. Cytological profiling of natural product scaffolds libraries for Parkinson’s disease
  333. Cytoprotection by Achyrocline satureioides (Lam) DC and some of its main flavonoids against oxidative stress
  334. Cytoprotective effects of phenolic antioxidants and essential fatty acids in human blood monocyte and neuroblastoma cell lines: Surrogates for neurological damage in …
  335. De B. Acetylcholinesterase inhibitory properties of black tea and its polyphenolic components
  336. Defective insulin signalling, mediated by inflammation, connects obesity to Alzheimer disease; relevant pharmacological therapies and preventive dietary …
  337. dementia IN SURINAME
  338. Dementia, preclinical studies in neurodegeneration and its potential for translational medicine in South America
  339. Design and characterization of enzymatic deglycosylation systems to produce drugs against Alzheimer’s disease
  340. Design and development of novel irreversible GSK-3β inhibitors to address Alzheimer’s disease
  341. Design and Molecular dynamic investigations of 7, 8-Dihydroxyflavone Derivatives as potential neuroprotective Agents Against Alpha-synuclein
  342. Design and Molecular dynamic Investigations of 7, 8-Dihydroxyflavone Derivatives as Potential neuroprotective Agents Against Alpha-synuclein
  343. Design and systhesis of nanoparticles for therapy and imaging of Alzheimer’s disease
  344. Design of Multi-target Directed Ligands as a Modern Approach for the Development of Innovative Drug Candidates for Alzheimer’s Disease
  345. Design, Synthesis and Biological Assessment of Ferulic Acid Derivatives as Inhibitors of β-Amyloid Oligomerization in Alzheimer’s Disease
  346. Design, synthesis and biological evaluation of 3-piperazinecarboxylate sarsasapogenin derivatives as potential multifunctional anti-Alzheimer agents
  347. Design, synthesis and biological evaluation of scutellarein derivatives as potential anti-Alzheimer’s disease candidates based on metabolic mechanism
  348. Design, synthesis and evaluation of 4′-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer’s disease treatment
  349. Design, synthesis and evaluation of chalcone Mannich base derivatives as multifunctional agents for the potential treatment of Alzheimer’s disease
  350. Designing multi-targeted therapeutics for the treatment of Alzheimer’s disease
  351. Destabilization of Alzheimer’s Aβ42 protofibrils with a novel drug candidate wgx-50 by molecular dynamics simulations
  352. Determination of Flavonoids
  353. Determination of total flavonoid content of different parts of Garcinia cowa
  354. Development and application of nano-flavor-drug carriers in Neurodegenerative diseases
  355. Development and validation of analytical methods for the identification and quantification of phenolic compounds from Euterpe oleracea fruits
  356. Development of a grape seed polyphenolic extract with anti‐oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies
  357. Development of Electrochemical Sensors for the Analysis of Therapeutic Compounds and Proteases related to Alzheimer’s disease
  358. Development of multifunctional molecules as potential therapeutic candidates for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis in the …
  359. Development of tau aggregation inhibitors for Alzheimer’s disease
  360. Development of technologies for the production of polyphenolic nutraceuticals from muscadine grapes and rabbiteye blueberries
  361. Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches
  362. Diabetes and Alzheimer’s disease: can tea phytochemicals play a role in prevention?
  363. Diet and brain health: which role for polyphenols?
  364. Diet And Lifestyle Guidelines And Desirable Levels Of Risk Factors And Protective Factors For Prevention Of Dementia-A Scientific Statement From Joint …
  365. Diet and medical foods in Parkinson’s disease
  366. Diet and Nutrition in Alzheimer’s Disease and Healthy Aging
  367. Diet and Nutrition in Alzheimer’s Disease and Healthy Aging
  368. Diet and nutrition in dementia and cognitive decline
  369. Diet and the Risk of Parkinson’s Disease—Research Suggests Dietary Interventions May Prevent It and Lessen Symptom Severity By Densie Webb, PhD, RD
  370. Diet, nutrients and metabolism: cogs in the wheel driving Alzheimer’s disease pathology?
  371. Dietary coconut and amyloid beta metabolism in the pathogenesis of Alzheimer’s disease
  372. Dietary Directions Against dementia Disorders
  373. Dietary factors in the etiology of Parkinson’s disease
  374. Dietary fatty acids and predementia syndromes
  375. Dietary fatty acids intake: possible role in cognitive decline and dementia
  376. Dietary fatty acids, cognitive decline, and dementia
  377. Dietary flavonoid intake in older adults: how many days of dietary assessment are required and what is the impact of seasonality?
  378. Dietary flavonoid intake to reduce the risk of chronic diseases
  379. Dietary flavonoids as potential neuroprotectants
  380. Dietary flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy
  381. Dietary intake of natural antioxidants: vitamins and polyphenols
  382. Dietary lipids and their oxidized products in Alzheimer’s disease
  383. Dietary modifications in Parkinson’s disease: A neuroprotective intervention?
  384. Dietary modulation of oxidative stress in Alzheimer’s disease
  385. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity
  386. Dietary phenolics in apples and cider and their bioavailability in healthy humans and subjects with an ileaostomy
  387. Dietary Plant Lectins May be an ‘Unknown Etiology’in Parkinson’s Disease and Dietary Bioactive Compounds Affect Lifespan and Fat Storage Aspects of …
  388. Dietary polyphenols and mitochondrial function: role in health and disease
  389. Dietary polyphenols and neurogenesis: Molecular interactions and implication for brain ageing and cognition
  390. Dietary polyphenols and the prevention of diseases
  391. Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects
  392. Dietary Polyphenols as Modulators of Brain Functions: Biological Actions and Molecular Mechanisms…
  393. Dietary polyphenols as potential remedy for dementia
  394. Dietary Polyphenols—Important Non-Nutrients in the Prevention of Chronic Noncommunicable Diseases. A Systematic Review
  395. Dietary Polyphenols: A Multifactorial Strategy to Target Alzheimer’s Disease
  396. Dietary polyphenols: A novel strategy to modulate microbiota-gut-brain axis
  397. Dietary Strategies and Supplements for the Prevention of Cognitive Decline and Alzheimer’s Disease
  398. Dietary supplementation of walnut partially reverses 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine induced neurodegeneration in a mouse model of Parkinson’s …
  399. Dietary supplementation with fruit polyphenolics ameliorates age-related deficits in behavior and neuronal markers of inflammation and oxidative stress
  400. Dietary Supplements as Cognitive Enhancers: The Role of Flavonoid-Rich Foods and their Relevance in Age-Related Neurodegeneration
  401. Dietary total prenylflavonoids from the fruits of Psoralea corylifolia L. prevents age-related cognitive deficits and down-regulates Alzheimer’s markers in SAMP8 mice
  402. Differential oxidative stress in oligodendrocytes and neurons after excitotoxic insults and protection by natural polyphenols
  403. Differential Protection among Fractionated Blueberry Polyphenolic Families against DA-, Aβ42- and LPS-Induced Decrements in Ca2+ Buffering in Primary …
  404. Direct Evaluation of Alzheimer’s Disease-Specific oxidative stress with Multiphoton Microscopy
  405. Discovery development of drugs for alzheimers disease neuroinflammation and elucidating their molecular mechanism of action
  406. Discovery of Gut Bacteria Specific to Alzheimer’s Associated Diseases is a Clue to Understanding Disease Etiology: Meta-Analysis of Population-Based Data on …
  407. Discovery of Natural Products from Curcuma longa that Protect Cells from Beta-Amyloid Insult: A Drug Discovery Effort against Alzheimer’s Disease
  408. Disease contraindication drug use behavior in patients with Parkinson’s disease
  409. Disruption of Calcium Homeostasis in Alzheimer’s Disease: Role of Channel Formation by β Amyloid Protein
  410. Dissecting molecular mechanisms in the living brain of dementia patients
  411. Divergent synthesis of biflavonoids yields novel inhibitors of the aggregation of amyloid β (1–42)
  412. Do polyphenols enter the brain and does it matter? Some theoretical and practical considerations
  413. Docking of GSK-3β with novel inhibitors, a target protein involved in Alzheimer’s disease
  414. Docking study and structure-activity relationships of human glutaminyl cyclase inhibitors for the drug discovery of Alzheimer’s disease
  415. Does Parkinson’s disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?
  416. Dopamine-Mediated oxidative stress Associated with Neurodegeneration in Parkinson Disease
  417. Dopaminergic Neuroprotection with Atremorine in Parkinson´ s Disease
  418. Down regulation effect of Rosmarinus officinalis polyphenols on cellular stress proteins in rat pheochromocytoma PC12 cells
  419. Down regulation effect of Rosmarinus officinalis polyphenols on cellular stress proteins in rat pheochromocytoma PC12 cells
  420. Dracocephalum moldavica L. and Melissa officinalis L.: Chemistry and bioactivities relevant in Alzheimer’s disease therapy
  421. Drug delivery systems for resveratrol, a non-flavonoid polyphenol: Emerging evidence in last decades
  422. Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer’s disease
  423. Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease
  424. Dual/multitargeted xanthone derivatives for Alzheimer’s disease: where do we stand?
  425. DYRK1A inhibition as potential treatment for Alzheimer’s disease
  426. Dysregulation of stress systems and nitric oxide signaling underlies neuronal dysfunction in Alzheimer’s disease
  427. Early vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer’s disease
  428. Eat to Beat Alzheimer’s
  429. EFEITO PROTETOR DO RESVERATROL NA DOENÇA DE ALZHEIMER
  430. Effect of Antioxidant Flavanone, Naringenin, from Citrus junos on Neuroprotection
  431. Effect of Black Raisins (Vitis vinifera) on Aluminum Chloride Induced Alzheimer’s Disease in Male Albino Rat.
  432. Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer’s disease in rats
  433. Effect of Chinese herbal medicine on Alzheimer’s disease
  434. Effect of dietary supplementation of dates in Alzheimer’s disease APPsw/2576 transgenic mice on oxidative stress and antioxidant status
  435. Effect of extraction procedures, genotypes and screening methods to measure the antioxidant potential and phenolic content of orange-fleshed sweetpotatoes …
  436. Effect of Imperatorin in Neuropathology of Parkinson’s Disease: An In Silico Study
  437. Effect of oil palm phenolics on beta amyloid deposition in cholesterol induced rat model of Alzheimer’s disease: Histological evidence
  438. Effect of phenolic-rich plant materials on protein and lipid oxidation reactions
  439. Effect of plant extracts on Alzheimer’s disease: An insight into therapeutic avenues
  440. Effect of polyphenols on oxidative stress and mitochondrial dysfunction in neuronal death and brain edema in cerebral ischemia
  441. Effect of polyphenols on protein misfolding
  442. Effects and mechanisms of actions of phytochemicals on Alzheimer’s disease neuropathology
  443. Effects and Possible Mechanisms of Some Phytochemicals on Drosophila Models of Alzheimer’s Disease
  444. Effects of berry polyphenols on cognitive function in humans
  445. Effects of Berry, Pomegranate, Grape and their Biophenols on Cognitive Function: A General Re-view
  446. Effects of biflavonoids from Garcinia madruno on a triple transgenic mouse model of Alzheimer’s disease
  447. Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia
  448. Effects of Dietary Components on Microglia Inactivation in Alzheimer’s Disease
  449. Effects of dietary docosahexaenoic acid supplementation on pathology and cognition in a mouse model of Alzheimer’s disease
  450. Effects of essential oils and aromatherapy on cognitive function in dementia: laboratory studies and application in aged care facility residents
  451. Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia
  452. Effects of flavonoids on MMP-13 Expression of IL-1β-treated Articular Chondrocytes and Their Cellular Mechanisms: Inhibition of c-Fos/AP-1 and JAK/STAT …
  453. Effects of green tea polyphenol on cognitive and acetylcholinesterase activities
  454. Effects of Horticultural Activities and Flower Tea Drinking Based on Reminiscent Storytelling on Demented Elders’ Cognitive and Emotional Functions
  455. Effects of huanglian-jie-du-tang and its modified formula on the modulation of amyloid-β precursor protein processing in Alzheimer’s disease models
  456. Effects of Isoflavone Extract from Fermented Soybean, Chungkukjang, on Cell Cycle Arrest and Apoptosis of MCF-7 Cells
  457. Effects of long-term administration of a cocoa polyphenolic extract (Acticoa powder) on cognitive performances in aged rats
  458. Effects of medicinal plants on Alzheimer’s disease and memory deficits
  459. Effects of peptides on the structure of lipid bilayers: Implication for its therapeutic effect in Alzheimer’s disease
  460. Effects of polyphenols on brain ageing and Alzheimer’s disease: focus on mitochondria
  461. Effects of resveratrol and other polyphenols on Sirt1: relevance to brain function during aging
  462. Effects of resveratrol and other polyphenols on the most common brain age-related diseases
  463. Effects of stilbenoid polyphenols (pterostilbene and gnetol) on cardiomyocyte hypertrophy in vitro and in vivo in spontaneously hypertensive heart failure rats
  464. Effects of tea catechins on Alzheimer’s disease: Recent updates and perspectives
  465. Effects of the flavonoids, silibinin and catechin, on the motility of extended cooled caprine sperm
  466. Effects of various flavonoids on the-synuclein fibrillation process
  467. Effects on Cognition of Berry, Pomegranate, Grape and Biophenols: A General Review
  468. EFFICACY STUDY OF BRAHMYADI YOGA IN THE MANAGEMENT OF Alzheimer’s DISEASE (SMRITI BHRAMSHA)
  469. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer’s disease
  470. Electroanalysis of α-Synuclein Aggregation Related to Parkinson’s Disease
  471. Electrochemical biosensors for the detection and study of α-synuclein related to Parkinson’s disease–A review
  472. Emerging role of polyphenolic compounds in the treatment of Neurodegenerative diseases: a review of their intracellular targets
  473. Emerging Signal Regulating Potential of Genistein against Alzheimer Disease: A Promising Molecule of Interest
  474. Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer’s disease
  475. Enhancing human cognition with cocoa flavonoids
  476. Enrichment of phenolic antioxidants from cranberry (Vaccinium macrocarpon) to improve biological functionality
  477. Epigallocatechin gallate (EGCG) inhibits alpha-synuclein aggregation: a potential agent for Parkinson’s disease
  478. Epigallocatechin-3-gallate and related phenol compounds redirect the amyloidogenic aggregation pathway of ataxin-3 towards non-toxic aggregates and prevent …
  479. Epigallocatechin-3-gallate, a promising molecule for Parkinson’s disease?
  480. Epigenetic drug discovery for Alzheimer’s disease
  481. Epigenetic effects of natural polyphenols: A focus on SIRT1‐mediated mechanisms
  482. ESPEN guidelines on nutrition in dementia
  483. Establishing a Connection between Alzheimer’s Disease and Cellular Energy Transduction
  484. Establishment of CD method for studies of amyloid-oligomerization process during Alzheimer disease
  485. Estimation of antioxidative properties of the natural polyphenols in the oxidation process of model liposome membranes
  486. Estimation of dietary flavonoid intake and major food sources of Korean adults
  487. Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: key role of neuron-glia crosstalk
  488. Ethanol extract of Epipremnum aureum leaves attenuate intranigral-rotenone induced Parkinson’s disease in rats
  489. Ethnobotanical treatment strategies against Alzheimer’s disease
  490. Ethnomedicinal Survey of Plants Used as Remedy for Alzheimer’s Disease in Ebonyi State, Nigeria
  491. Ethnopharmacological approaches for dementia therapy and significance of natural products and herbal drugs
  492. Eupatilin: a natural pharmacologically active flavone compound with its wide range applications
  493. Evaluating the neuroprotective effects of fermented rooibos herbal tea in Wistar rats exposed to bisphenol-A during gestation and lactation
  494. Evaluation of anti-oxidant activities and total phenolic content of Chromolaena odorata
  495. Evaluation of antioxidant activities and total phenolic content of methanolic extract of Rhodiola heterodanta roots
  496. evaluation of antiparkinson activity of hesperetin pyridoxine against olanzepine and manganese induced parkinsonism
  497. Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer’s disease
  498. Evaluation of Memory Enhancing Activity of Methanolic Extract of Oxalis corniculata Linn on dementia in Experimental Animals
  499. Evaluation of plant phenolic metabolites as a source of Alzheimer’s drug leads
  500. Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays
  501. Evaluation to the antioxidant activity of total flavonoids extract from persimmon (Diospyros kaki L.) leaves
  502. Evidence of neuroprotective effects of saffron and crocin in a Drosophila model of parkinsonism
  503. Evidence of oxidative stress in Alzheimer’s disease brain and antioxidant therapy: lights and shadows
  504. Evolutionary medicine’perspectives on Alzheimer’s Disease: Review and new directions
  505. Exploration of Mitochondrial Dysfunction, Depolarization and Polyphenols by Creative Synthesis for Product Development
  506. Exploring the benefits of cellular models to uncover bioactive polyphenols for neurodegeneration
  507. Exploring the bioavailability of (poly) phenols from berries and their potential activities in humans
  508. Exploring the efficacy of natural products in alleviating Alzheimer’s disease
  509. Exploring the mechanism of flavonoids through systematic bioinformatics analysis
  510. Exploring the potential of marine microbes in clinical management of Alzheimer’s disease: A road map for bioprospecting and identifying promising isolates
  511. Extra-virgin olive oil for potential prevention of Alzheimer disease
  512. Extra-virgin olive oil for potential prevention of Alzheimer disease
  513. Factors affecting the levels of tea polyphenols and caffeine in tea leaves
  514. Fate of microbial metabolites of dietary polyphenols in rats: is the brain their target destination?
  515. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer’s disease
  516. Ferulic Acid and Alzheimer’s Disease: Promises and Pitfalls
  517. Fight Alzheimer’s with Vitamins and Antioxidants
  518. Fight Parkinson’s and Huntington’s with Vitamins and Antioxidants
  519. First synthesis of the antiangiogenic homoisoflavanone, cremastranone
  520. Flavan-3-ol compounds from wine wastes with in vitro and in vivo antioxidant activity
  521. Flavanols, mild cognitive impairment, and Alzheimer’s dementia
  522. Flavanonol glucosides from the aerial parts of Agrimonia pilosa Ledeb. and their acetylcholinesterase inhibitory effects
  523. Flavins and flavoproteins: applications in medicine
  524. Flavone: An Important Scaffold for Medicinal Chemistry
  525. Flavones from root of Scutellaria baicalensis Georgi: drugs of the future in neurodegeneration?
  526. Flavones from the root of Scutellaria baicalensis Georgi—drug of the future in neurodegeneration and neuroprotection
  527. Flavones: An important scaffold for medicinal chemistry
  528. flavonoid baicalein attenuates activation-induced cell death of brain microglia
  529. flavonoid bioactivity: transport across blood-brain-barrier and neuroprotective effects. In vivo studies
  530. flavonoid enhances the glyoxalase pathway in cerebellar neurons to retain cellular functions
  531. flavonoid hesperidin induces synapse formation and improves memory performance through the astrocytic TGF-β1
  532. flavonoid in enhancing memory function
  533. flavonoid inhibitors of alpha-synuclein fibrillation: A therapeutic strategy for Parkinson’s disease, and, The effect of membranes on SMA fibrillation
  534. flavonoid Intake and Dementia
  535. flavonoid intake and disability-adjusted life years due to Alzheimer’s and related dementias: a population-based study involving twenty-three developed countries
  536. flavonoid modulation of GABAA receptors
  537. flavonoid transport across blood-brain barrier: Implication for their direct neuroprotective actions
  538. flavonoid transport across RBE4 cells: a blood-brain barrier model
  539. flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia
  540. Flavonoid-based therapies in the early management of Neurodegenerative diseases
  541. Flavonoid-rich foods (FRF): A promising nutraceutical approach against lifespan-shortening diseases
  542. Flavonoidal Compound Derived from Chrysanthemum indicum L. Suppresses MUC5AC Mucin Gene Expression, Production and Secretion from Cultured …
  543. Flavonoids
  544. flavonoids and Aging
  545. flavonoids and anthranquinones as xanthine oxidase and monoamine oxidase inhibitors: a new approach towards inflammation and oxidative stress
  546. flavonoids and brain health: multiple effects underpinned by common mechanisms
  547. flavonoids and cognition: potential therapeutic role in Alzheimer’s disease
  548. flavonoids and cognition: the molecular mechanisms underlying their behavioural effects
  549. flavonoids and cognitive function: a review of human randomized controlled trial studies and recommendations for future studies
  550. flavonoids and dementia: an update
  551. flavonoids and Diarylheptanoids: neuroprotective Activities of Phytochemicals
  552. flavonoids and neuroprotection: biochemical and population-based analyses of potential neuroprotective factors related to dementia.
  553. flavonoids and Phenolic Acids as Potential Natural Antioxidants
  554. flavonoids and the aging brain
  555. flavonoids and the brain: Evidences and putative mechanisms for a protective capacity
  556. flavonoids and their relation to human health
  557. flavonoids as acetylcholinesterase inhibitors: Current therapeutic standing and future prospects
  558. flavonoids as detoxifying and pro-survival agents: What’s new?
  559. flavonoids as modulators of memory and learning: molecular interactions resulting in behavioural effects
  560. flavonoids as neuroprotective and therapeutic agents against aging related neurological disorders
  561. flavonoids as novel neuroprotective nutraceuticals
  562. flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders
  563. flavonoids as regulators of amyloid precursor protein processing
  564. flavonoids as therapeutic agents in Alzheimer’s and Parkinson’s diseases: a systematic review of preclinical evidences
  565. flavonoids in Foods and Their Role in Healthy Nutrition
  566. flavonoids in human health: from structure to biological activity
  567. flavonoids in neurodegeneration: Limitations and strategies to cross CNS barriers
  568. flavonoids in the treatment of Alzheimer’s and other Neurodegenerative diseases
  569. flavonoids in Transgenic Alzheimer’s Disease Mouse Models
  570. flavonoids in Transgenic Alzheimer’s Disease Mouse Models
  571. flavonoids inhibit heparin-induced aggregation of the third repeat (r3) of microtubule-binding domain of Alzheimer’s tau protein
  572. flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells: a comparison of different flavonoids in activating estrogenic effect and in …
  573. flavonoids with Novel Nicotinic Activity as Potential Pharmacotherapies to Treat Ethanol-Induced Neurotoxicity
  574. Flavonoids-food sources and health benefits
  575. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease
  576. Flavonoids: an overview
  577. Flavonoids: Broad Spectrum Agents on Chronic Inflammation
  578. Flavonoids: important biocompounds in food
  579. Flavonoids: its working mechanism and various protective roles
  580. Flavonoids: modulators of brain function?
  581. Flavonol Glycosides and Phenolic Compounds from Euphorbia maculata
  582. Flavonol-rich dark cocoa significantly decreases plasma endothelin-1 and improves cognition in urban children
  583. Food antioxidants and Alzheimer’s disease
  584. Food, polyphenols and neuroprotection
  585. Forestalling the Epidemics of Parkinson’s Disease Through Plant-Based Remedies
  586. Formation of the 42-mer Amyloid 𝜷 Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer’s Disease
  587. Formulation development and optimization of novel drug delivery systems for the treatment of alzheimers disease
  588. Free radical scavenging activity and qualitative analysis of polyphenols by RP-HPLC in the flowers of Couroupita guianensis Abul.
  589. Free radical–mediated damage to brain in Alzheimer’s disease: role of acrolein and preclinical promise of antioxidant polyphenols
  590. Free radicals and polyphenols: The redox chemistry of Neurodegenerative diseases
  591. From the baker to the bedside: yeast models of Parkinson’s disease
  592. Fruit and vegetable intake and its association with dementia in the English Longitudinal Study of Ageing
  593. Fruit polyphenols and their effects on neuronal signaling and behavior in senescence
  594. Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer’s disease
  595. Functions of flavonoids in the central nervous system: astrocytes as targets for natural compounds
  596. Future Therapeutic Perspectives into the Alzheimer’s Disease Targeting the oxidative stress Hypothesis
  597. Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibitory Activity on Alzheimer’s Amyloid β‐Peptide Aggregation
  598. Gene-environment interaction research and transgenic mouse models of Alzheimer’s disease
  599. GENERAL PRACTITIONER’S APPROACH TO DIAGNOSIS, DISCLOSURE AND MANAGEMENT OF dementia IN THE
  600. Genetics of iron regulation and the possible role of iron in Parkinson’s disease
  601. Genistein ameliorates learning and memory deficits in amyloid β (1–40) rat model of Alzheimer’s disease
  602. Ginger components as anti-Alzheimer drugs: focus on drug design
  603. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo‐controlled double‐blind study
  604. Ginkgo biloba as an alternative medicine in the treatment of anxiety in dementia and other psychiatric disorders
  605. Ginkgo biloba extract in Alzheimer’s disease: from action mechanisms to medical practice
  606. Gold Nanoparticles and Peptoids as Novel Inhibitors of Amyloid Beta Aggregation in Alzheimer’s Disease
  607. Gold nanoparticles and peptoids as novel inhibitors of Aβ aggregation in Alzheimer’s disease
  608. Gold Nanoparticles in Diagnosis and Treatment of Alzheimer’s Disease
  609. Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer’s disease
  610. Green Tea confers Protection on the Retina in MPTP Mice Model of Parkinson’s Disease
  611. Green tea intake and risks for dementia, Alzheimer’s disease, mild cognitive impairment, and cognitive impairment: A systematic review
  612. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate induces neurorescue of long‐term serum‐deprived PC12 cells and promotes neurite outgrowth
  613. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration
  614. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate promotes the rapid protein kinase C‐and proteasome‐mediated degradation of Bad: implications for …
  615. Green tea polyphenols enhance sodium nitroprusside‐induced neurotoxicity in human neuroblastoma SH‐SY5Y cells
  616. Green tea polyphenols prevent Parkinson’s disease: in vitro and in vivo studies
  617. GRP78/BIP/HSPA5 as a Therapeutic Target in Models of Parkinson’s Disease: A Mini Review
  618. Gut microbiota mediated allostasis prevents stress-induced neuroinflammatory risk factors of Alzheimer’s disease.
  619. Gut microbiota, cognitive frailty and dementia in older individuals: a systematic review
  620. Health benefits of nongallated and gallated flavan-3-ols: a prospectus
  621. Health effects of foods rich in polyphenols
  622. Healthy Eating to Reduce the Risk of Dementia
  623. Hepatoprotective effects of apple polyphenol extract on aluminum-induced liver oxidative stress in the rat
  624. Herbal treatment of Parkinsonism: a review
  625. Herbs and dementia: a focus on Chinese and other traditional herbs
  626. Herbs and Nutrients for Neurologic Disorders: Treatment Strategies for Alzheimer’s, Parkinson’s, Stroke, Multiple Sclerosis, Migraine, and Seizures
  627. Hesperetin, a citrus flavonoid, attenuates LPS-induced neuroinflammation, apoptosis and memory impairments by modulating TLR4/NF-κB signaling
  628. Hesperidin, a citrus flavonoid, protects against l-methionine-induced hyperhomocysteinemia by abrogation of oxidative stress, endothelial dysfunction and …
  629. Heterogeneity in gut microbiota drive polyphenol metabolism that influences α-synuclein misfolding and toxicity
  630. High concentrations of a urinary biomarker of polyphenol intake are associated with decreased mortality in older adults
  631. Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents
  632. Hippocampal neurogenesis in Alzheimer’s disease: is there a role for dietary modulation?
  633. Histological Evidence Of The Effect Of Oil Palm Phenolics In Atherogenic Diet Induced Rat Model Of Alzheimer’s Disease
  634. HPLC-DAD fingerprinting analysis, antioxidant activities of Tithonia diversifolia (Hemsl.) A. Gray leaves and its inhibition of key enzymes linked to Alzheimer’s …
  635. HPLC-PDA isolation and LC-MS/MS detection of an acetylcholinesterase inhibitory flavonoid from Tephrosia purpurea (L.) Pers. in zebrafish brain
  636. Human Tau Isoform Aggregation and Selective Detection of Misfolded Tau from Post-Mortem Alzheimer’s Disease Brains
  637. Hypericum perforatum improve memory and learning in Alzheimer’s model:(experimental study in mice)
  638. Hypericum perforatum phenolic compounds: protective role in the toxicity induced by heterologous expression of α-synuclein and huntingtin in yeast cells
  639. Hyperphosphorylation of Tau Protein in Down’s dementia and Alzheimer’s disease: methylation and implications in prevention and therapy
  640. Identification of 5-methoxyflavone as a novel DNA polymerase-beta inhibitor and neuroprotective agent against beta-amyloid toxicity
  641. Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer’s disease
  642. Identification of polyphenolic compounds and black tea extract as potent inhibitors of lipid membrane destabilization by Aβ 42 aggregates
  643. IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients
  644. Il trattamento con RSV e l’espressione transgenica di PGC-1α proteggono i neuroni dopaminergici nel modello MPTP murino del morbo di Parkinson.
  645. Immuno-modulatory effects of microbial metabolites of flavan-3-ols and dimeric procyanidins
  646. Impact of Diet on the Pathogenesis of Alzheimer’s Disease
  647. Impact of flavonoids on cellular and molecular mechanisms underlying age-related cognitive decline and neurodegeneration
  648. Impact of heat treatment on selected vegetables: bioaccessibility of (poly) phenolic compounds after in vitro gastrointestinal digestion and colonic microbiota …
  649. Impact of plant-derived flavonoids on Neurodegenerative diseases
  650. Implication of green tea as a possible therapeutic approach for Parkinson disease
  651. Implications for Degenerative Disorders: Antioxidative Activity, Total Phenols, Flavonoids, Ascorbic Acid, β-Carotene and β-Tocopherol in Aloe vera
  652. Implications of polyphenols on endogenous antioxidant defense systems in human diseases
  653. Improved mitochondrial function in brain aging and Alzheimer disease-the new mechanism of action of the old metabolic enhancer piracetam
  654. In search of therapeutic solutions for Alzheimer’s disease
  655. In silico investigation of the pharmacological mechanisms of beneficial effects of Ginkgo biloba L. on Alzheimer’s Disease
  656. In silico studies applied to natural products with potential activity against Alzheimer’s disease
  657. In vitro anti-nitrosative, antioxidant, and cytotoxicity activities of plant flavonoids: a comparative study
  658. In vitro antioxidant activity and total phenolic content of ethanolic leaf extract of Stevia rebaudiana Bert.
  659. In vitro antioxidant, anti-diabetes, anti-dementia, and inflammation inhibitory effect of Trametes pubescens fruiting body extracts
  660. In vitro enzyme inhibition potentials and antioxidant activity of synthetic flavone derivatives
  661. In vitro evaluation of extracts from Mentha species for potential treatment of Alzheimer’s disease
  662. In vitro peroxynitrite scavenging activity of 6-hydroxykynurenic acid and other flavonoids fromGingko biloba yellow leaves
  663. In vivo antioxidant activity of total flavonoids from indocalamus leaves in aging mice caused by D-galactose
  664. In Vivo Characterization of CLR01, an Aggregation and Toxicity Inhibitor, with anAlzheimer’s Disease Focus
  665. In Vivo Imaging Agents Based on flavonoids for Amyloid’s Plaques in the Brains of Patients with Alzheimer’s Disease
  666. In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a randomized controlled trial
  667. In-depth investigation of the binding of flavonoid taxifolin with bovine hemoglobin at physiological pH: Spectroscopic and molecular docking studies
  668. In-Vitro Assessment Of Phenolic, Flavonoid, Flavonolic Contents And Antioxidant Activities Of Plant Pleurotus Ostreatus For Neurodegenerative Disorders
  669. In-vitro cholinesterase inhibitory activity of dry fruit extract of Phyllanthus emblica relevant to the treatment of Alzheimer’s disease
  670. In-vitro evaluation of acetylcholinesterase inhibition and antioxidant activity of selected Palestinian medicinal plants: Implications for Alzheimer’s disease …
  671. In-Vitro Evaluation of Cholinesterase Inhibitory and Antioxidant Activities of Tamarindus indica for the Treatment of Alzheimer’s Disease
  672. In-vitro screening of acetylcholinesterase inhibitory activity of extracts from Palestinian indigenous flora in relation to the treatment of Alzheimer’s disease
  673. In‐vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer’s disease
  674. Indian Herbal Medicines used for Treatment of Dementia: An Overview
  675. Indian herbs and their therapeutic potential against Alzheimer’s Disease and other neurological disorders
  676. Indoleamine 2, 3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer’s disease hippocampus
  677. Induction of neuronal differentiation of murine N2a cells by two polyphenols present in the mediterranean diet mimicking neurotrophins activities: resveratrol and …
  678. Inflammaging as a prodrome to Alzheimer’s disease
  679. Inflammation in Alzheimer’s Disease, and Prevention with Antioxidants and Phenolic Compounds–What Are the Most Promising Candidates?
  680. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications
  681. Inflammation: role in Parkinson’s disease and target for therapy
  682. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons: possible relevance to the etiology of Parkinson’s disease
  683. INFLUENCE OF EXTRACT AND PHENOL GLYCOSIDES FROM ROSE PETALS ON THE FIBRILS OF AMYLOID PEPTIDE Aβ (1-42). STUDY BY …
  684. Influence of hesperidin combined with Sinemet on genetical and biochemical abnormalities in rats suffering from Parkinson’s disease
  685. Influence of nitrogen fertilizer micro‐dosing on phenolic content, antioxidant, and anticholinesterase properties of aqueous extracts of three tropical leafy vegetables
  686. Influences of Diet, Exercise, and Stress on Hippocampal Health in Depression and Alzheimer’s Disease
  687. inhibition and antioxidant activity of selected Palestinian medicinal plants: Implications for Alzheimer’s disease therapy
  688. Inhibition and disaggregation of α‐synuclein oligomers by natural polyphenolic compounds
  689. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism
  690. Inhibition of early upstream events in prodromal Alzheimer’s disease by use of targeted antioxidants
  691. Inhibition of Hepatic Insulin Resistance by Licorice flavonoids as Mediated by PTP1B Repression
  692. Inhibition of Rat Prostate Testosterone 5α-Reductase Activity by Isoflavonoids
  693. Inhibition of α-Synuclein contributes to the ameliorative effects of dietary flavonoids luteolin on arsenite-induced apoptotic cell death in the dopaminergic PC12 cells
  694. Inhibitory Effect of a flavonoid Dihydromyricetin against Aβ40 Amyloidogenesis and Its Associated Cytotoxicity
  695. Inhibitory Effects of Bombusae concretio Salicea on Neuronal Secretion of Alzheimer’s β-Amyloid Peptides, a Neurodegenerative Peptide
  696. Inhibitory Effects of Isoflavonoids on Rat Prostate Testosterone 5α-Reductase
  697. Inhibitory Mechanism for Amyloid β42 Aggregation by Catechol-type Flavonoids
  698. Inhibitory potential of plant secondary metabolites against Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural …
  699. Inhibitory properties of phenolic compounds against enzymes linked with human diseases
  700. Insights on Metal Ions and Misfolded Proteins in Alzheimer’s Disease Using flavonoid Derivatives and X-ray Fluorescence Microscopy.
  701. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance
  702. Intake of flavonoids and risk of dementia
  703. Intake of flavonoids and risk of dementia
  704. Interaction between 24‐hydroxycholesterol, oxidative stress, and amyloid‐β in amplifying neuronal damage in Alzheimer’s disease: three partners in crime
  705. Interaction between flavonoids and the blood–brain barrier: in vitro studies
  706. Interaction of polyphenols with other food components as a means for their neurological health benefits
  707. Interaction of α-synuclein with Rhus typhina tannin–Implication for Parkinson’s disease
  708. Interplay between Alpha-Synuclein and oxidative stress in Parkinson´ s Disease Cell Models
  709. Intranasal therapeutic strategies for management of Alzheimer’s disease
  710. Investigating blood plasma levels of cytokines and amyloid-β as potential diagnostic biomarkers for preclinical Alzheimer’s disease
  711. Investigating the neuroprotective effect of plant (poly) phenols in models of Parkinson´ s disease
  712. Investigation of an Interaction of flavonoids on the Antioxidant Activity of Alpha Tocopherol
  713. Investigation of anti-inflammatory compounds from food and plant libraries for use in Alzheimer’s disease
  714. Investigation of in-vitro antioxidant potential in crotalaria verrucosa along with identification and quantification of its polyphenolic compounds
  715. Investigational α-synuclein aggregation inhibitors: hope for Parkinson’s disease
  716. Investigations of anticholinestrase and antioxidant potentials of methanolic extract, subsequent fractions, crude saponins and flavonoids isolated from Isodon …
  717. Involvement of astrocytes in Alzheimer’s disease from a neuroinflammatory and oxidative stress perspective
  718. Iridoid Glycosides and Phenolic Glycosides from Buddleja asiatica with Anti-inflammatory and Cytoprotective Activities
  719. Iridoids and other monoterpenes in the Alzheimer’s brain: Recent development and future prospects
  720. Iron as a therapeutic target for Parkinson’s disease
  721. Iron dysregulation in Alzheimer’s disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein …
  722. Is pharmacological prevention of Alzheimer’s a realistic goal?
  723. Isoflavones and Alzheimer’s disease: the effects of soy in diet
  724. Isolation of eupatorin (3′,5-dihydroxy-4′,6,7-trimethoxyflavone) from Albizia odoratissima and its application for l-tryptophan sensing
  725. Isolation of flavonoides from Artemisia macrocephala anticholinesterase activity: Isolation, characterization and its in vitro anticholinesterse activity supported by …
  726. Isolation, synthesis, and metabolism of polyphenols: Stilbenoids, gallotannins and ellagitannins
  727. Kaempferol attenuates cognitive deficit via regulating oxidative stress and neuroinflammation in an ovariectomized rat model of sporadic dementia
  728. Lamiaceae family plants as a potential anticholinesterase source in the treatment of Alzheimer’s disease
  729. Lamiaceae phenols as multifaceted compounds: bioactivity, industrial prospects and role of “positive-stress”
  730. Lavandula stoechas (L) a Very Potent Antioxidant Attenuates dementia in Scopolamine Induced Memory Deficit Mice
  731. Liberation of copper from amyloid plaques: making a risk factor useful for Alzheimer’s disease treatment
  732. Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer’s disease
  733. Lifestyle patterns as a modifiable risk factor for late-life cognitive decline: A narrative review regarding dementia prevention
  734. Lifestyle-related factors in predementia and dementia syndromes
  735. Links between insulin resistance, lipoprotein metabolism and amyloidosis in Alzheimer’s Disease
  736. Lipid Peroxidation and Mitochondrial Dysfunction in Alzheimer’s and Parkinson’s Diseases: Role of Natural Products as Cytoprotective Agents
  737. Liposomal flavonoid in Combating Age-Related Cerebral Oxidative Damage
  738. Literature Evidence and ARRIVE Assessment on neuroprotective Effects of Flavonols in Neurodegenerative Diseases’ Models
  739. Literature Evidence and Arrive Assessment on neuroprotective Effects of Flavonols Quercetin, Rutin and Isoquercitrin in Neurodegenerative Diseases’ Models
  740. Literature-related discovery: common factors for Parkinson’s disease and Crohn’s disease
  741. Literature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease
  742. Long-term dietary supplementation of pomegranates, figs and dates alleviate neuroinflammation in a transgenic mouse model of Alzheimer’s disease
  743. Long-term naringin consumption reverses a glucose uptake defect and improves cognitive deficits in a mouse model of Alzheimer’s disease
  744. Low Phytanic Acid-Concentrated DHA Prevents Cognitive Deficit and Regulates Alzheimer Disease Mediators in an ApoE−/− Mice Experimental Model
  745. Low-Molecular Weight Metabolites from Polyphenols as Effectors for Attenuating Neuroinflammation
  746. Macroalgae as a Valuable Source of Naturally Occurring Bioactive Compounds for the Treatment of Alzheimer’s Disease
  747. Macronutrients, aluminium from drinking water and foods, and other metals in cognitive decline and dementia
  748. Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent
  749. Management of cognitive determinants in senile dementia of Alzheimer’s type: therapeutic potential of a novel polyherbal drug product
  750. Management of oxidative stress and other pathologies in Alzheimer’s disease
  751. Mangiferin: a multipotent natural product preventing neurodegeneration in Alzheimer’s and Parkinson’s disease models
  752. Mannosylated liposomal flavonoid in combating age-related ischemia–reperfusion induced oxidative damage in rat brain
  753. MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide
  754. Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer’s disease
  755. Mechanisms of aging and potential role of selected polyphenols in extending healthspan
  756. Mechanisms of dietary flavonoid action in neuronal function and neuroinflammation
  757. Mechanisms of neuroprotection by polyphenols
  758. Mechanistic description of natural herbs in the treatment of dementia: A systematic review
  759. Medical management of Parkinson’s disease: focus on neuroprotection
  760. Medicinal chemistry approaches for the treatment and prevention of Alzheimer’s disease
  761. Medicinal plants and Alzheimer’s disease: Integrating ethnobotanical and contemporary scientific evidence
  762. Medicinal plants and dementia therapy: herbal hopes for brain aging?
  763. Medicinal plants as protective strategies against Parkinson’s disease
  764. Medicinal plants from northeastern Brazil against Alzheimer’s disease
  765. Medicinal Plants from Northeastern Brazil against Alzheimer’s Disease
  766. Medicinal plants of Brazil and Alzheimer’s disease: Evolution in traditional use and pre-clinical studies
  767. Medicinal Plants with Acetylcholinesterase Inhibitory Activity: Therapeutic Potential of Brazilian Plants for the Treatment of Alzheimer’s Disease
  768. Medicinal Plants, Phytochemicals and Alzheimer’s
  769. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and …
  770. Mediterranean and MIND diets containing olive biophenols reduces the prevalence of Alzheimer’s disease
  771. Mediterranean diet and risk for Alzheimer’s disease
  772. Mediterranean Diet as a Potential Strategy to Reduce Cognitive Decline and dementia in Elderly
  773. Mediterranean diet in predementia and dementia syndromes
  774. Mediterranean diet, cognitive function, and dementia: a systematic review
  775. Mediterranean diet: The role of long-chain ω-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins …
  776. Memory-enhancing activities of the aqueous extract of Albizia adianthifolia leaves in the 6-hydroxydopamine-lesion rodent model of Parkinson’s disease
  777. Metabolic and immune risk factors for dementia and their modification by flavonoids: New targets for the prevention of cognitive impairment?
  778. Metabolic links between diabetes and Alzheimer’s disease
  779. Metabolic syndrome and the role of dietary lifestyles in Alzheimer’s disease
  780. Metabolomics analysis of Xanthoceras sorbifolia husks protection of rats against Alzheimer’s disease using liquid chromatography mass spectrometry
  781. Metal Binding of flavonoids and Their Distinct Inhibition Mechanisms Toward the Oxidation Activity of Cu2+–β-Amyloid: Not Just Serving as Suicide Antioxidants!
  782. Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or …
  783. Metal chelation, radical scavenging and inhibition of Aβ42 fibrillation by food constituents in relation to Alzheimer’s disease
  784. Metal dyshomeostasis and inflammation in Alzheimer’s and Parkinson’s diseases: possible impact of environmental exposures
  785. Metal dysregulation in the pathogenesis of Alzheimers disease An experimental study in rat brain and cultured neuroblastoma cells
  786. Metal ions and metal complexes in Alzheimer’s disease
  787. Metals and amyloid‐β in Alzheimer’s disease
  788. Methanolic extract of Hibiscus asper leaves improves spatial memory deficits in the 6-hydroxydopamine-lesion rodent model of Parkinson’s disease
  789. Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s disease
  790. MICE MODEL OF Parkinson’s DISEASE
  791. Microwave assisted extraction of flavonoids from cultivated Epimedium sagittatum: Extraction yield and mechanism, antioxidant activity and chemical composition
  792. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study
  793. MIND food and speed of processing training in older adults with low education, the MINDSpeed Alzheimer’s disease prevention pilot trial
  794. Mitigating Alzheimer’s disease with natural polyphenols: a review
  795. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer’s disease
  796. Mitochondria as potential targets in Alzheimer disease therapy: An update
  797. Mitochondria as targets for neuronal protection against excitotoxicity: a role for phenolic compounds?
  798. Mitochondria in neuroprotection by phytochemicals: bioactive polyphenols modulate mitochondrial apoptosis system, function and structure
  799. Mitochondria-targeted protective compounds in Parkinson’s and Alzheimer’s diseases
  800. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease
  801. Mitochondrial cascade hypothesis of Alzheimer’s disease: myth or reality?
  802. Mitochondrial Dysfunction and Alpha-Lipoic Acid: Beneficial or Harmful in Alzheimer’s Disease?
  803. Mitochondrial dysfunction in Parkinson’s disease: pathogenesis and neuroprotection
  804. Mitochondrial dysfunction—a pharmacological target in Alzheimer’s disease
  805. Mitochondrial dysfunction: cause and consequence of Alzheimer’s
  806. Mitochondrial dysfunction: cause and consequence of Alzheimer’s disease
  807. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease—therapeutic aspects
  808. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer’s disease?
  809. Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols
  810. Mitochondrial Therapeutic Approaches in Parkinson’s Disease
  811. Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer’s disease
  812. Modulating Effect of Diet on Alzheimer’s Disease
  813. Modulation of Alzheimer-like Pathology in Type 2 Diabetic Rats via Grape Seed or Ginseng Extracts
  814. Modulation of endogenous antioxidant system by wine polyphenols in human disease
  815. Modulation of mitochondrial calcium as a pharmacological target for Alzheimer’s disease
  816. Modulation of multiple neuroinflammatory signalling pathways by the dietary glycosidic flavonoid tiliroside
  817. MODULATION OF NEUROINFLAMMATION BY MEDICINAL HERBS AND FLAVONOIDS
  818. Modulation of Nrf2 by olive oil and wine polyphenols and neuroprotection
  819. Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and Neurodegenerative disorders
  820. Modulation of Pro-inflammatory Mediators by Eugenol in AlCl3 Induced dementia in Rats
  821. Molecular characterization of multi-targets by bis (7)-tacrineat amyloid β cascade associated with Alzheimer’s disease
  822. Molecular Mechanism of the Inhibition of EGCG on the Alzheimer Aβ1–42 Dimer
  823. Molecular mechanisms of the neuroprotective/neurorescue action of multi-target green tea polyphenols
  824. Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer’s disease
  825. Molecular mechanisms underlying the flavonoid-induced inhibition of α-synuclein fibrillation
  826. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression
  827. Molecular pharmacology of rosmarinic and salvianolic acids: Potential seeds for Alzheimer’s and vascular dementia drugs
  828. Molecular study of cell culture models of Parkinson’s disease and Huntington’s disease.
  829. Molecular targets in Alzheimer’s disease: from pathogenesis to therapeutics
  830. Monoamine oxidase and α-synuclein as targets in Parkinson’s disease therapy
  831. Monoamine Oxidase B and Free Radical Scavenging Activities of Natural flavonoids in Melastoma candidum D. Don
  832. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies
  833. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies
  834. Mucuna pruriens seeds in treatment of Parkinson’s disease: pharmacological review
  835. Mulberry fruit extract protects against memory impairment and hippocampal damage in animal model of vascular dementia
  836. Multi-target directed drugs as a modern approach for drug design towards Alzheimer’s disease: an update
  837. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer’s disease
  838. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer’s disease
  839. Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer’s disease
  840. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer’s disease drugs
  841. Multifunctional neuroprotective–neurorescue drugs for Parkinson’s disease
  842. Multiple pharmacological activities of Caesalpinia crista against aluminium-induced neurodegeneration in rats: Relevance for Alzheimer’s disease
  843. Multipotent natural agents to combat Alzheimer’s disease. Functional spectrum and structural features1
  844. Na+‐K+‐ATPase, a potent neuroprotective modulator against Alzheimer disease
  845. Nano-delivery systems for encapsulation of dietary polyphenols: An experimental approach for Neurodegenerative diseases and brain tumors
  846. Nano-encapsulation of a natural polyphenol, green tea catechins: way to preserve its antioxidative potential
  847. Nanoformulations of polyphenols for prevention and treatment of cardiovascular and metabolic disorders
  848. Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer’s Disease
  849. Nanoparticle formulations in the diagnosis and therapy of Alzheimer’s disease
  850. Nanoparticles as nanocarriers of resveratrol for Alzheimer’s disease
  851. Nanotechnology and Alzheimer’s Disease: What has been Done and What to Do’
  852. Nanotechnology based Theranostic approaches in Alzheimer’s disease management: current status and future perspective
  853. Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
  854. Nanotherapeutic strategies for the treatment of Alzheimer’s disease
  855. Nardostacys Jatamansi DC Protects from the loss of memory and cognition deficits in sleep deprived Alzheimer’s disease (Ad) mice model
  856. Naringenin ameliorates Alzheimer’s disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin …
  857. Naringin ameliorates memory deficits in experimental paradigm of Alzheimer’s disease by attenuating mitochondrial dysfunction
  858. Natural Antioxidants in Dementia: An Overview
  859. Natural compounds and plant extracts as therapeutics against chronic inflammation in Alzheimer’s disease–a translational perspective
  860. Natural compounds and their derivatives as multifunctional agents for the treatment of alzheimer disease
  861. Natural Compounds as Beneficial Antioxidant Agents in Neurodegenerative Disorders: A Focus on Alzheimer’s Disease
  862. Natural compounds for Alzheimer’s disease therapy: a systematic review of preclinical and clinical studies
  863. Natural Compounds for the Management of Parkinson’s Disease and Attention-Deficit/Hyperactivity Disorder
  864. Natural Neuroprotectives for the Management of Parkinson’s Disease
  865. Natural phenolic compounds as therapeutic and preventive agents for cerebral amyloidosis
  866. Natural phytochemicals in the treatment and prevention of dementia: An overview
  867. Natural Phytoestrogens: A Class of Promising neuroprotective Agents for Parkinson Disease
  868. Natural plant-derived acetylcholinesterase inhibitors: Relevance for Alzheimer’s disease
  869. Natural polyphenols against Neurodegenerative disorders: potentials and pitfalls
  870. Natural polyphenols binding to amyloid: A broad class of compounds to treat different human amyloid diseases
  871. Natural polyphenols effects on protein aggregates in Alzheimer’s and Parkinson’s prion-like diseases
  872. Natural polyphenols in the treatment of Alzheimer’s disease
  873. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation
  874. Natural Product Chemical Probe Discovery against Parkinson’s Disease
  875. Natural product formulations for the prevention and treatment of Alzheimer’s disease: a patent review
  876. Natural product polyphenols of relevance to human health
  877. Natural products against Alzheimer’s disease: Pharmaco-therapeutics and biotechnological interventions
  878. Natural products and derivatives affecting neurotransmission relevant to Alzheimer’s and Parkinson’s disease
  879. Natural products and their derivatives as multifunctional ligands against Alzheimer’s disease
  880. Natural products as a source of Alzheimer’s drug leads
  881. Natural products as promising drug candidates for the treatment of Alzheimer’s disease: molecular mechanism aspect
  882. Natural products combating neurodegeneration: Parkinson’s disease
  883. Natural Products for the Treatment of Alzheimer’s Disease: Present and Future Expectations
  884. Natural Products for Treatment of Alzheimer’s Disease
  885. Natural products in Alzheimer’s disease therapy: would old therapeutic approaches fix the broken promise of modern medicines?
  886. Natural Products-Based Drugs: Potential Therapeutics against Alzheimer’s Disease and other Neurological Disorders
  887. Natural stilbenes effects in animal models of Alzheimer’s disease
  888. Natural Therapeutics for Alzheimer’s Disease
  889. Naturally Inspired Privileged Structures in Drug Discovery: Multifunctional Compounds for Alzheimer’s Disease Treatment
  890. Nature as a source of metabolites with cholinesterase‐inhibitory activity: an approach to Alzheimer’s disease treatment
  891. neuro Protective Role of Selected medicinal Plant In Alzheimers Disease Design of Novel Drugs
  892. Neuro-nutrients as anti-Alzheimer’s disease agents: A critical review
  893. Neurobiological aspects of Alzheimer’s disease
  894. Neurobiological effects of Hyperforin and its potential in Alzheimer’s disease therapy
  895. Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits
  896. Neurocognitive improvement through plant food bioactives: A particular approach to Alzheimer’s disease
  897. Neurodegenerative diseases: might citrus flavonoids play a protective role?
  898. Neurogenesis and neuroprotection in postischemic brain neurodegeneration with Alzheimer phenotype: is there a role for curcumin
  899. Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer’s disease
  900. Neurogenic traditional Chinese medicine as a promising strategy for the treatment of Alzheimer’s disease
  901. Neuroinflammation in Alzheimer’s disease: the preventive and therapeutic potential of polyphenolic nutraceuticals
  902. Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention
  903. Neuroinflammatory processes in cognitive disorders: Is there a role for flavonoids and n-3 polyunsaturated fatty acids in counteracting their detrimental effects?
  904. Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases
  905. Neuronal death in Alzheimer’s disease and therapeutic opportunities
  906. Neuronutrition and Alzheimer’s disease
  907. Neuropharmacological Activity of Apium graveolens L. and its neuroprotective Effect on MPTP-Induced Parkinson-Like Symptoms
  908. Neuropharmacological properties and pharmacokinetics of the citrus flavonoids hesperidin and hesperetin—a mini-review
  909. Neuroprotection by natural polyphenols: molecular mechanisms
  910. Neuroprotection in Alzheimer Disease
  911. Neuroprotection of brain-targeted bioactive dietary artoindonesianin O (AIO) from mulberry on rat neurons as a novel intervention for Alzheimer’s disease
  912. Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway
  913. neuroprotective actions of flavones and flavonols: mechanisms and relationship to flavonoid structural features
  914. neuroprotective actions of flavonoids
  915. neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice
  916. neuroprotective attributes of L-theanine, a bioactive amino acid of tea, and its potential role in Parkinson’s disease therapeutics
  917. neuroprotective effect and antioxidant activity of Passiflora edulis fruit flavonoid fraction, aqueous extract, and juice in aluminum chloride-induced Alzheimer’s …
  918. neuroprotective effect of blackberry (Rubus sp.) polyphenols is potentiated after simulated gastrointestinal digestion
  919. neuroprotective effect of brassica oleracea sprouts crude juice in a cellular model of Alzheimer’s disease
  920. neuroprotective effect of cocoa flavonids on in vitro oxidative stress
  921. neuroprotective effect of EGb761® and low-dose whole-body γ-irradiation in a rat model of Parkinson’s disease
  922. neuroprotective effect of ellagic acid against chronically scopolamine induced Alzheimer’s type memory and cognitive dysfunctions: possible behavioural and …
  923. neuroprotective effect of flavonoids via up-regulation of Nrf2-ARE pathway, in MPP+-induced PC12 cells
  924. neuroprotective Effect of Flavonoids: A Systematic Review
  925. neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson’s disease
  926. neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of Alzheimer’s …
  927. neuroprotective effect of hesperidin on aluminium chloride induced Alzheimer’s disease in Wistar rats
  928. neuroprotective effect of naringin, a dietary flavonoid against 3-nitropropionic acid-induced neuronal apoptosis
  929. neuroprotective effect of natural products against Alzheimer’s disease
  930. neuroprotective effect of olive oil polyphenols in Alzheimer’s disease
  931. neuroprotective effect of phytic acid in Parkinson’s disease
  932. neuroprotective effects associated with wine and its phenolic constituents
  933. neuroprotective effects of amantadine–flavonoid conjugates
  934. neuroprotective effects of citrus Fruit-Derived flavonoids, nobiletin and Tangeretin in Alzheimer’s and Parkinson’s Disease
  935. neuroprotective effects of digested polyphenols from wild blackberry species
  936. neuroprotective effects of epigallocatechin gallate in cell culture and animal models of Parkinson’s disease
  937. neuroprotective effects of fisetin in Alzheimer’s and Parkinson’s Diseases: From chemistry to medicine
  938. neuroprotective effects of naturally occurring polyphenols on quinolinic acid‐induced excitotoxicity in human neurons
  939. neuroprotective effects of phenolic and carboxylic acids on oxidative stress-induced toxicity in human neuroblastoma SH-SY5Y cells
  940. neuroprotective Effects of Polyphenols
  941. neuroprotective Effects of Polyphenols in Aging and Age‐Related Neurological Disorders
  942. neuroprotective Effects of Quercetin in Alzheimer’s Disease
  943. neuroprotective effects of resveratrol and epigallocatechin gallate polyphenols are mediated by the activation of protein kinase C gamma
  944. neuroprotective effects of resveratrol in Alzheimer disease pathology
  945. neuroprotective effects of rutin and quercetin flavonoids in glaucium corniculatum methanol and water extracts
  946. neuroprotective effects of selected microbial-derived phenolic metabolites and aroma compounds from wine in human sh-sy5y neuroblastoma cells and their …
  947. neuroprotective mechanisms of resveratrol in Alzheimer’s disease: role of SIRT1
  948. neuroprotective natural products for the treatment of Parkinson’s disease by targeting the autophagy–lysosome pathway: A systematic review
  949. neuroprotective potential of withania somnifera in rotenone induced parkinsonism in mice
  950. neuroprotective properties of a standardized extract from Myracrodruon urundeuva Fr. All.(Aroeira-Do-Sertao), as evaluated by a Parkinson’s disease model in rats
  951. neuroprotective properties of dietary polyphenols in Parkinson’s disease
  952. neuroprotective Properties of Partridgeberry (Vaccinium vitis-idaea L. var. minus Lodd) Polyphenols
  953. neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease
  954. neuroprotective role of antioxidant and pyranocarboxylic acid derivative against AlCl3 induced Alzheimer’s disease in rats
  955. neuroprotective Role of Green Tea Polyphenols on the Superior Colliculus in MPTP Mice Model of Parkinson’s Disease
  956. neuroprotective role of natural polyphenols
  957. neuroprotective strategies in Parkinson’s disease
  958. neuroprotective Strategies in Parkinson’s Disease Using the Models of 6‐Hydroxydopamine and MPTPa
  959. neuroprotective Strategies in Parkinson’s Disease Using the Models of 6‐Hydroxydopamine and MPTPa
  960. neuroprotective strategies to prevent and treat Parkinson’s disease based on its pathophysiological mechanism
  961. neuroprotective therapies for Alzheimer’s disease
  962. Neurosupportive role of vanillin, a natural phenolic compound, on rotenone induced neurotoxicity in SH-SY5Y neuroblastoma cells
  963. Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
  964. New acetylcholinesterase inhibitors for Alzheimer’s disease
  965. New methodology for the biomimetic synthesis of Flavan-3, 4-diols and derivatives
  966. NF-κB-Mediated Neuroinflammation in Parkinson’s Disease and Potential Therapeutic Effect of Polyphenols
  967. Nitric oxide mediates neurovascular coupling in the brain effect of polyphenols in animal models of Alzheimer’s disease
  968. Nonpeptide neurotrophic agents useful in the treatment of Neurodegenerative diseases such as Alzheimer’s disease
  969. Nonpharmacological Modulation of Chronic Inflammation in Parkinson’s Disease: Role of Diet Interventions
  970. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease
  971. Nootropic and anti-Alzheimer’s actions of medicinal plants: molecular insight into therapeutic potential to alleviate Alzheimer’s neuropathology
  972. Nootropic Medicinal Plants: Therapeutic Alternatives for Alzheimer’s disease
  973. Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer’s disease treatment
  974. Novel chelators targeting cell cycle arrest, acetylcholinesterase, and monoamine oxidase for Alzheimer’s therapy
  975. Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
  976. Novel Mannitol-Based Small Molecules for Inhibiting Aggregation of α-Synuclein Amyloids in Parkinson’s Disease
  977. Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties
  978. Novel neuroprotective Therapies for Alzheimer’s and Parkinsons’s Disease
  979. Novel photoaffinity probes of homoisoflavonoids for target identification of retinal neovascularization
  980. Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease
  981. Novel regimen through combination of memantine and tea polyphenol for neuroprotection against brain excitotoxicity
  982. Novel tacrine-scutellarin hybrids as multipotent anti-Alzheimer’s agents: Design, synthesis and biological evaluation
  983. Novel tactics for neuroprotection in Parkinson’s disease: role of antibiotics, polyphenols and neuropeptides
  984. Novel targets for parkinsonism-depression comorbidity
  985. Novel therapeutic strategies for dementia
  986. Novel Therapeutics in Alzheimer’s Disease
  987. Nutraceutical potential of phenolics from′ brava′ and′ mansa′ extra-virgin olive oils on the inhibition of enzymes associated to Neurodegenerative disorders in …
  988. Nutraceutical Potential of Phenolics fromBrava´ andMansa´ Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in …
  989. Nutraceuticals and amyloid Neurodegenerative diseases: a focus on natural phenols
  990. Nutraceuticals and their preventive or potential therapeutic value in Parkinson’s disease
  991. Nutraceuticals in cognitive impairment and Alzheimer’s
  992. Nutraceuticals in cognitive impairment and Alzheimer’s disease
  993. Nutraceuticals in the Prevention or Treatment of Parkinson’s Disease
  994. Nutraceuticals Neuroprotect Naturally: Alzheimer’s disease, Parkinson’s disease, Stroke and Major Depressive Disorder
  995. Nutraceuticals: a novel concept in prevention and treatment of Alzheimer’s disease and related disorders
  996. Nutraceuticals: an emerging therapeutic approach against the pathogenesis of Alzheimer’s disease
  997. Nutraceuticals: dietary flavonoids
  998. Nutrients in the Prevention of Alzheimer’s Disease
  999. Nutrition and AGE-ing: Focusing on Alzheimer’s Disease
  1000. Nutrition and the risk for Parkinson’s disease: review of the literature
  1001. Nutrition and the risk of Alzheimer’s disease
  1002. Nutrition increases Survival and Reverses NAFLD and Alzheimer’s disease
  1003. Nutrition Society Silver Medal Lecture Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain
  1004. Nutrition: Review on the possible treatment for Alzheimer’s disease
  1005. Nutritional and pharmacological strategies to regulate microglial polarization in cognitive aging and Alzheimer’s disease
  1006. Nutritional approaches to combat oxidative stress in Alzheimer’s disease
  1007. Nutritional approaches to modulate oxidative stress in Alzheimer’s disease
  1008. Nutritional contributions to dementia prevention: main issues on antioxidant micronutrients
  1009. Nutritional habits, risk, and progression of Parkinson disease
  1010. Nutritional prevention of cognitive decline and dementia
  1011. O-Methylated flavonoid Isorhamnetin Protects against oxidative stress via Activation of Nrf2 and Target Gene Expression
  1012. Oil palm phenolics inhibit the in vitro aggregation of β-amyloid peptide into oligomeric complexes
  1013. Old age-associated phenotypic screening for Alzheimer’s disease drug candidates identifies sterubin as a potent neuroprotective compound from Yerba santa
  1014. Olive biophenols reduces Alzheimer’s pathology in SH-SY5Y cells and APPswe mice
  1015. Olive polyphenols: New promising agents to combat aging-associated neurodegeneration
  1016. Omics and Epigenetics of Polyphenol-Mediated Neuroprotection: The Curcumin Perspective
  1017. On the role of synthesized hydroxylated chalcones as dual functional amyloid-β aggregation and ferroptosis inhibitors for potential treatment of Alzheimer’s disease
  1018. ON THE THERAPEUTIC PROPERTIES OF NATURALLY OCCURRING FLAVONOID-QUERCETIN: A MAGICAL THERAPEUTIC AGENT
  1019. One‐compound‐multiple‐targets strategy to combat Alzheimer’s disease
  1020. Original Research Phenolics, antioxidant and anti-inflammatory activities of Melia azedarachextracts
  1021. Orobol: An Isoflavone Exhibiting Regulatory Multifunctionality against Four Pathological Features of Alzheimer’s Disease
  1022. Orthosiphon stamineus improves memory in scopolamine-induced amnesia model of cholinergic hypothesis of Alzheimer’s disease
  1023. Outsmarting Alzheimer’s: What You Can Do to Reduce Your Risk
  1024. Overview of Alzheimer’s disease and some therapeutic approaches targeting Aβ by using several synthetic and herbal compounds
  1025. Overviews of biological importance of quercetin: A bioactive flavonoid
  1026. Oxidant/antioxidant imbalance and the risk of Alzheimer’s disease
  1027. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8‐hydroxyguanine levels in substantia nigra
  1028. Oxidative modification of vesicular transporters in an animal model of Alzheimer’s disease
  1029. oxidative stress and Alzheimer’s disease: dietary polyphenols as potential therapeutic agents
  1030. oxidative stress and amyloid beta toxicity in Alzheimer’s disease: intervention in a complex relationship by antioxidants
  1031. oxidative stress and inflammation: what polyphenols can do for us?
  1032. oxidative stress and neuroinflammation in Alzheimer’s disease and amyotrophic lateral sclerosis: From biology to therapeutic strategies
  1033. oxidative stress events and neuronal dysfunction in Alzheimer’s disease: focus on APE1/Ref-1-mediated survival strategies
  1034. oxidative stress in Alzheimer patients in different stages of the disease
  1035. oxidative stress in Alzheimer’s Disease: A Review on Emergent Natural Polyphenolic Therapeutics
  1036. oxidative stress in Alzheimer’s disease: implications for prevention and therapy
  1037. oxidative stress in Parkinson’s disease
  1038. oxidative stress in Parkinson’s disease
  1039. oxidative stress in Parkinson’s disease; parallels between current animal models, human studies and cells
  1040. Oxidative stress: a bridge between Down’s syndrome and Alzheimer’s disease
  1041. Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease
  1042. Parkinson’s disease and tea: a quantitative review
  1043. Parkinson’s Disease Model in vitro and in C. elegans
  1044. Parkinson’s Disease-associated LRRK2 Mutation Causes Abnormal Protein Accumulation-related Cytotoxicity
  1045. Parkinson’s disease: from pathogenesis to pharmacogenomics
  1046. Parkinson’s disease: the emerging role of gut dysbiosis, antibiotics, probiotics, and fecal microbiota transplantation
  1047. Partridgeberry polyphenols protect primary cortical and hippocampal neurons against β-amyloid toxicity
  1048. Past and Present Drug Development for Alzheimer’s Disease
  1049. Pelargonidin improves memory deficit in amyloid β25-35 rat model of Alzheimer’s disease by inhibition of glial activation, cholinesterase, and oxidative stress
  1050. Pelargonidin improves passive avoidance task performance in a rat amyloid beta25-35 model of Alzheimer’s disease via estrogen receptor independent pathways
  1051. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer’s disease
  1052. Pharmacoepigenomic interventions as novel potential treatments for Alzheimer’s and Parkinson’s diseases
  1053. Pharmacogenomics in Alzheimer’s disease
  1054. Pharmacogenomics of Alzheimer’s disease: Novel therapeutic strategies for drug development
  1055. Pharmacokinetics and Tissue Distribution of 14C-Labeled Grape Polyphenols in the Periphery and the Central Nervous System Following Oral Administration
  1056. PHARMACOLOGICAL ACTIVITY OF NATURAL PRODUCTS IN VITRO AND IN ANIMAL MODELS OF Parkinson’s DISEASE AND DEPRESSION
  1057. Pharmacological effects of active components of Chinese herbal medicine in the treatment of Alzheimer’s disease: a review
  1058. PHARMACOLOGICAL EVALUATION OF TRIPHALA CHURNA INSTREPTOZOTOCIN (ICV) INDUCED dementia IN RATS
  1059. Pharmacological Investigation and Unraveling Mechanism of Action ofJasminum sambac Flowers for Predicated Treatment of Alzheimer’s Disease
  1060. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson’s disease
  1061. Pharmacological properties and therapeutic potential of naringenin: a citrus flavonoid of pharmaceutical promise
  1062. PHARMACOLOGY OF OLIVE BIOPHENOLS IN Alzheimer’s DISEASE PREVENTION AND TREATMENT
  1063. Pharmacophore-based drug design of novel potential tau ligands for Alzheimer’s disease treatment
  1064. Pharmacotherapies for Alzheimer’s disease: beyond cholinesterase inhibitors
  1065. Pharmacotherapies for Alzheimer’s Disease: From Natural Compounds to Target Synthetic Drugs
  1066. Phenolic Acid Intake, Delivered Via Moderate Champagne Wine Consumption, Improves Spatial Working Memory Via the Modulation of Hippocampal and Cortical …
  1067. Phenolic acids exert anticholinesterase and cognition-improving effects
  1068. Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity
  1069. Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein
  1070. Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein
  1071. Phenolic composition, antioxidant and enzyme inhibitory activities of acetone, methanol and water extracts of Clinopodium vulgare L. subsp. vulgare L.
  1072. Phenolic compounds and their health benefits: A review
  1073. Phenolic compounds characteristic of the mediterranean diet in mitigating microglia-mediated neuroinflammation
  1074. Phenolic compounds from edible algae: Bioactivity and health benefits
  1075. Phenolic Compounds from the Leaves and Stems of Desmodium Caudatum
  1076. Phenolic compounds in fruits and beverages consumed as part of the mediterranean diet: their role in prevention of chronic diseases
  1077. Phenolic compounds in fruits and beverages consumed as part of the mediterranean diet: their role in prevention of chronic diseases
  1078. Phenolic compounds of green tea: Health benefits and technological application in food
  1079. Phenolic compounds prevent Alzheimer’s pathology through different effects on the amyloid-β aggregation pathway
  1080. Phenolic compounds prevent the oligomerization of α‐synuclein and reduce synaptic toxicity
  1081. Phenolic Compounds with IL-6 Inhibitory Activity from Akebia quinata
  1082. Phenolic content of grapevine leaves (Vitis labrusca var. Bordo) and its neuroprotective effect against peroxide damage
  1083. Phenolic content, enzyme inhibitory and antioxidative activity potentials of Phlomis nissolii and P. pungens var. pungens
  1084. Phenolic contents and bioactive potential of peach fruit extracts
  1085. Phenolic contents, antioxidant and anticholinesterase potentials of crude extract, subsequent fractions and crude saponins from Polygonum hydropiper L
  1086. Phenolic Extracts from Clerodendrum volubile Leaves Inhibit Cholinergic and Monoaminergic Enzymes Relevant to the Management of Some Neurodegenerative …
  1087. Phenolic profile and antioxidative properties of pulp and seeds of Randia monantha Benth
  1088. Phenolic profile of three wild edible mushroom extracts from Ordu, Turkey and their antioxidant properties, enzyme inhibitory activities
  1089. Phenolic, flavonoid contents, anticholinesterase and antioxidant evaluation of Iris germanica var; florentina
  1090. Phenylpropanoids and Alzheimer’s disease: A potential therapeutic platform
  1091. Phloretin attenuates behavior deficits and neuroinflammatory response in MPTP induced Parkinson’s disease in mice
  1092. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer’s disease
  1093. Phosphorylation and sequence dependency of neurofilament protein oxidative modification in Alzheimer disease
  1094. Phyto‐Tacrine Hybrids as Promising Drugs to Treat Alzheimer’s Disease
  1095. Phytochemical and pharmacological properties of flavonols
  1096. Phytochemical Evaluation of Lagerstroemia indica (L.) Pers. Leaves as Anti-Alzheimer’s
  1097. Phytochemicals and cognitive health: Are flavonoids doing the trick?
  1098. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer’s disease
  1099. Phytochemicals Bridging Autophagy Induction and Alpha-Synuclein Degradation in Parkinsonism
  1100. Phytochemicals, Antioxidants, and Cholinesterase Inhibitory Profiles of Elatostema Papillosum Leaves: An Alternative Approach for Management of Alzheimer’s …
  1101. Pinus halepensis essential oil attenuates the toxic Alzheimer’s amyloid beta (1-42)-induced memory impairment and oxidative stress in the rat hippocampus
  1102. PLANT BASED INDIAN TRADITIONAL MEDICINE FOR Neurodegenerative DISEASES-A NOVEL APPROACH TO TREAT ALZHEIMER
  1103. Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson’s Disease Models
  1104. Plant phenolics affect oxidation of tryptophan
  1105. Plant phenolics as functional food ingredients
  1106. Plant polyphenols as dietary antioxidants in human health and disease
  1107. Plant polyphenols as dietary modulators of brain functions
  1108. Plant polyphenols as natural drugs for the management of Down syndrome and related disorders
  1109. Plants as potential sources for drug development against Alzheimer’s disease
  1110. Plants traditionally used in age-related brain disorders (dementia): an ethanopharmacological survey
  1111. Plants with traditional uses and activities, relevant to the management of Alzheimer’s disease and other cognitive disorders
  1112. Plasma antioxidant status in patients with Alzheimer’s disease and cognitively intact elderly: a meta-analysis of case-control studies
  1113. Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease
  1114. Plasticity of hippocampal synaptic transmission and intrinsic excitability in a mouse model of Alzheimer’s disease
  1115. Polymethoxyflavones: Novel β-secretase (BACE1) inhibitors from citrus peels
  1116. polyphenol amentoflavone affords neuroprotection against neonatal hypoxic‐ischemic brain damage via multiple mechanisms
  1117. polyphenol antioxidants from natural sources and contribution to health promotion
  1118. polyphenol composition, antioxidant and bioplaguicide activities of the solid residue from hydrodistillation of Rosmarinus officinalis L.
  1119. polyphenol compounds and PKC signaling
  1120. polyphenol health effects on cardiovascular and Neurodegenerative disorders: A review and meta-analysis
  1121. polyphenol modulation of blood flow and oxygenation
  1122. polyphenol Pharmacokinetics and Cardiovascular, Cognitive and Exercise Pharmacodynamics following Montmorency Tart Cherry Intake in Humans
  1123. polyphenol stilbenes: molecular mechanisms of defence against oxidative stress and aging-related diseases
  1124. Polyphenol-enriched cocoa protects the diabetic retina from glial reaction through the sirtuin pathway
  1125. Polyphenol-rich Boswellia serrata gum prevents cognitive impairment and insulin resistance of diabetic rats through inhibition of GSK3β activity, oxidative …
  1126. Polyphenol-rich foods in the Mediterranean diet are associated with better cognitive function in elderly subjects at high cardiovascular risk
  1127. Polyphenolic antioxidants and neuronal regeneration
  1128. Polyphenolic Compound from Vitis vinifera L. have Potential for the Alzheimer Disease Treatment
  1129. Polyphenolic compounds for treating Neurodegenerative disorders involving protein misfolding
  1130. Polyphenols and brain health
  1131. Polyphenols and cognitive function
  1132. Polyphenols and health: new and recent advances
  1133. Polyphenols and human health: a review
  1134. Polyphenols and human health: prevention of disease and mechanisms of action
  1135. Polyphenols and inflammation
  1136. Polyphenols and Metabolites Enhance Survival in Rodents and Nematodes—Impact of Mitochondria
  1137. Polyphenols and Neurodegenerative diseases
  1138. Polyphenols and Neurodegenerative Diseases
  1139. Polyphenols and neuroprotection against ischemia and neurodegeneration
  1140. Polyphenols and public health
  1141. Polyphenols and the human brain: plant “secondary metabolite” ecologic roles and endogenous signaling functions drive benefits
  1142. Polyphenols as acetylcholinesterase inhibitors: structural specificity and impact on human disease
  1143. Polyphenols As Natural, Dual-Action Therapeutics For Alzheimer’s Disease
  1144. Polyphenols beyond barriers: a glimpse into the brain
  1145. Polyphenols derived from lychee seed suppress Aβ (1-42)-induced neuroinflammation
  1146. Polyphenols for diabetes associated neuropathy: Pharmacological targets and clinical perspective
  1147. Polyphenols from Food and Natural Products: Neuroprotection and Safety
  1148. Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative
  1149. Polyphenols in dementia: From molecular basis to clinical trials
  1150. Polyphenols in disease: from diet to supplements
  1151. Polyphenols in health and disease: practice and mechanisms of benefits
  1152. Polyphenols in neurodegeneration and neuroendocrine alterations: a metabolomic approach
  1153. Polyphenols in Parkinson’s disease: A systematic review of in vivo studies
  1154. Polyphenols in the Prevention of Alzheimer’s Disease: some food for thought?
  1155. Polyphenols Modulate Alzheimer’s Amyloid Beta Aggregation in a Structure-Dependent Manner
  1156. Polyphenols neuroprotective effect in a Parkinson’s disease yeast model: phosphoproteome alterations
  1157. Polyphenols suppress and modulate inflammation: possible roles in health and disease
  1158. Polyphenols Targeting Brain Cells Longevity, Brain’s Redox Status, and Neurodegenerative Diseases
  1159. Polyphenols-What’s Behind their Antiaging Brain Reputation
  1160. Polyphenols: a diverse class of multi-target anti-HIV-1 agents
  1161. Polyphenols: Food sources and health benefits
  1162. Polyphenols: multipotent therapeutic agents in Neurodegenerative diseases
  1163. Polyphenols: well beyond the antioxidant capacity: gallic acid and related compounds as neuroprotective agents: you are what you eat!
  1164. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer’s disease
  1165. Pomegranate’s neuroprotective effects against Alzheimer’s disease are mediated by urolithins, its ellagitannin-gut microbial derived metabolites
  1166. Possible involvement of programmed cell death pathways in the neuroprotective action of polyphenols
  1167. Possible role of common spices as a preventive and therapeutic agent for Alzheimer’s disease
  1168. Possible therapeutic role of grape (Vitis vinifera) leaves polyphenolic extract in the regression of aluminium-induced Alzheimer’s disease in rats
  1169. Possible Therapeutic Uses of Salvia triloba and Piper nigrum in Alzheimer’s Disease–Induced Rats
  1170. Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer’s disease
  1171. Potent Inhibitory Effect of flavonoids in Scutellaria baicalensis on Amyloid β Protein-Induced Neurotoxicity
  1172. Potential application of dietary polyphenols from red wine to attaining healthy ageing
  1173. Potential beneficial effects of a diet with walnuts in aging and Alzheimer’s disease
  1174. Potential complementarity of high-flavanol cocoa powder and spirulina for health protection
  1175. Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro
  1176. Potential health benefits of tea polyphenols—a review
  1177. Potential of medicinal plant compounds to targeting Tau protein in the therapy of Alzheimer’s disease–A review
  1178. Potential of South African medicinal plants targeting the reduction of Aβ42 protein as a treatment of Alzheimer’s disease
  1179. Potential protection of green tea polyphenols against 1800 MHz electromagnetic radiation-induced injury on rat cortical neurons
  1180. Potential role of (-)-epigallocatechin-3-gallate (EGCG) in the secondary prevention of Alzheimer disease
  1181. Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease
  1182. Potential role of olive oil phenolic compounds in the prevention of Neurodegenerative diseases
  1183. Potential Role of Vitamin C in the Prevention of Alzheimer’s Disease
  1184. Potential therapeutic strategies for Alzheimer’s disease targeting or beyond β-amyloid: insights from clinical trials
  1185. Potential therapeutic strategies to prevent the progression of alzheimer to disease states
  1186. Precautionary Ellagic Acid Treatment Ameliorates Chronically Administered Scopolamine Induced Alzheimer’s Type Memory and Cognitive Dysfunctions in …
  1187. Preclinical and potential applications of common western herbal supplements as complementary treatment in Parkinson’s disease
  1188. Precursor form of brain‐derived neurotrophic factor and mature brain‐derived neurotrophic factor are decreased in the pre‐clinical stages of Alzheimer’s disease
  1189. Prediction of Anti‐Alzheimer’s Activity of flavonoids Targeting Acetylcholinesterase in silico
  1190. Prenylated flavonoids from the Roots of Sophora flavescens Promote Vascular Relaxation via Endothelium-Dependent Mechansims
  1191. Pretreatment with natural flavones and neuronal cell survival after oxidative stress: a structure− activity relationship study
  1192. Prevention and reversal of Alzheimer’s disease: treatment protocol
  1193. Prevention and treatment of Alzheimer disease and aging: antioxidants
  1194. Prevention of Dementia
  1195. Prevention of oxidative injury by flavonoids from stems and leaves of Scutellaria Baicalensis georgi in PC12 cells
  1196. Preventive and Therapeutic Effects of Traditional Medicines on Diabetic Complications: Sophora flavescens, Pueraria lobata, Coptis chinensis, Cirsium …
  1197. Preventive effect of small-leaved kuding tea (Ligustrum robustum (Roxb.) Bl.) polyphenols on D-galactose-induced oxidative stress and aging in mice
  1198. PREVENTIVE EFFECTS OF GREEN TEA CATECHINS ON DEMENTIA
  1199. Primary Prevention of Alzheimer’s Disease (AD)
  1200. Processing of the β‐amyloid precursor protein and its regulation in Alzheimer’s disease
  1201. Profiling of in vitro neurobiological effects and phenolic acids of selected endemic Salvia species
  1202. Progress in drug development for Alzheimer’s disease: an overview in relation to mitochondrial energy metabolism
  1203. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset.
  1204. Proposed Mechanism of Alzheimer’s Disease: the Role of oxidative stress A Review of Scientific Literature
  1205. Prospective associations between single foods, Alzheimer’s dementia and memory decline in the elderly
  1206. Protection of Okadaic Acid-induced Tau Hyperphosphorylation by Bioflavonoids in Neuroblastoma Cells
  1207. Protective effect of a (poly) phenol-rich extract derived from sweet cherries culls against oxidative cell damage
  1208. Protective effect of a phenolic‐rich fraction from Schisandra chinensis against H2O2‐induced apoptosis in SH‐SY5Y cells
  1209. Protective effect of black tea extract against aluminium chloride-induced Alzheimer’s disease in rats: A behavioural, biochemical and molecular approach
  1210. Protective effect of daidzein against streptozotocin‐induced Alzheimer’s disease via improving cognitive dysfunction and oxidative stress in rat model
  1211. Protective effect of ginger (Zingiber officinale) on Alzheimer’s disease induced in rats
  1212. Protective Effect of Green Tea Extract on Neuronal Cell Death in Alzheimer Model using -amyloid Peptide
  1213. Protective effect of green tea polyphenol EGCG against neuronal damage and brain edema after unilateral cerebral ischemia in gerbils
  1214. Protective effect of iris germanica l. In β-amyloid-induced animal model of Alzheimer’s disease
  1215. Protective effect of isoflavones from Trifolium pratense on dopaminergic neurons
  1216. Protective effect of kaempferol on the transgenic Drosophila model of Alzheimer’s disease
  1217. Protective effect of mulberry crude extract against nonylphenol-induced thyroid disruption by inhibiting the activity of deiodinase in rats
  1218. Protective effect of naringin, a citrus flavonoid, against colchicine-induced cognitive dysfunction and oxidative damage in rats
  1219. Protective effect of Picrorhiza kurroa on Alzheimer’s disease induced by aluminium chloride in rats
  1220. Protective effect of raisin (currant) against spatial memory impairment and oxidative stress in Alzheimer disease model
  1221. Protective effect of rutin, a polyphenolic flavonoid against haloperidol‐induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical …
  1222. Protective effect of standardized extract of Passiflora incarnata flower in Parkinson’s and Alzheimer’s disease
  1223. Protective Effect of the Leaves of Solanum torvums wartz on Drosophila melanogaster against β-Amyloid Induced Alzheimer Disease
  1224. Protective effects of berry polyphenols against age-related cognitive impairment
  1225. Protective effects of dietary polyphenols in human diseases and mechanisms of action
  1226. Protective effects of fisetin and other berry flavonoids in Parkinson’s disease
  1227. Protective effects of flavonoid baicalein against menadione-induced damage in SK-N-MC cells
  1228. Protective effects of flavonoids against Alzheimer’s disease-related neural dysfunctions
  1229. Protective effects of foods containing flavonoids on age-related cognitive decline
  1230. Protective effects of gingerol on streptozotocin-induced sporadic Alzheimer’s disease: emphasis on inhibition of β-amyloid, COX-2, alpha-, beta-secretases …
  1231. Protective effects of Indian spice curcumin against amyloid-β in Alzheimer’s disease
  1232. Protective effects of Portulaca oleracea against rotenone mediated depletion of glutathione in the striatum of rats as an animal model of Parkinson’s disease
  1233. Protective effects of water extract of propolis on dopaminergic neurons, brain derived neurotrophic factor and stress oxidative factors in the rat model of Parkinson’s …
  1234. Protective role of caffeic acid in an Aβ25-35-induced Alzheimer’s disease model
  1235. Protein drug targets of lavandula angustifolia on treatment of rat Alzheimer’s disease
  1236. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds
  1237. Proteomics in traditional Chinese medicine with an emphasis on Alzheimer’s disease
  1238. Putative role of red wine polyphenols against brain pathology in Alzheimer’s and Parkinson’s disease
  1239. Quercetin enrich diet during the early-middle not middle-late stage of Alzheimer’s disease ameliorates cognitive dysfunction
  1240. Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer’s disease
  1241. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution
  1242. Rational approach to discover multipotent anti-Alzheimer drugs
  1243. Rational Design, Preparation, and Analysis of Chemical Reagents for Investigating Multiple Pathological Factors in Alzheimer’s Disease
  1244. Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson’s disease
  1245. Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region
  1246. Recent advances from metabolomics and lipidomics application in Alzheimer’s disease inspiring drug discovery
  1247. Recent advances in health promoting effect of dietary polyphenols
  1248. Recent advances in herbal medicines treating Parkinson’s disease
  1249. Recent Advances in Multi-target Anti-Alzheimer Disease Compounds (2013 Up to the Present)
  1250. Recent Advances in Nanoencapsulation Systems Using PLGA of Bioactive Phenolics for Protection against Chronic Diseases
  1251. Recent advances in the antioxidant therapies for Alzheimer’s disease: Emphasis on natural antioxidants
  1252. Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer’s disease therapy
  1253. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer’s?
  1254. Recent advances in the genetics of Parkinson’s disease
  1255. Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer’s disease
  1256. Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer’s Disease
  1257. Recent findings in Alzheimer disease and nutrition focusing on epigenetics
  1258. Recent Plant Based Remedies for Alzheimer’s Disease, Parkinson’s Disease and Cerebral Ischemic Stroke
  1259. Recent progress in multifunctional metal chelators as potential drugs for Alzheimer’s disease
  1260. Recent Studies on Mechanisms of New Drug Candidates for Alzheimer’s Disease Interacting with Amyloid-β Protofibrils Using Molecular Dynamics Simulations
  1261. Recent trends in drug discovery against Alzheimer’s disease: use of natural products and nutraceuticals from botanicals
  1262. Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson’s disease
  1263. Recent updates on the association between Alzheimer’s disease and vascular dementia
  1264. Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
  1265. Receptor specific, stimuli responsive and subcellular targeted approaches for effective therapy of Alzheimer: Role of surface engineered nanocarriers
  1266. Recovery of new diarylheptanoid sources in Betulaceae: Characterisation of the phenolic profile of Corylus species by HPLC-ESI-MS methods
  1267. Recycling acetate for improving flavanones production from Escherichia coli
  1268. Red grape juice and Alzheimer’s disease
  1269. Red wine polyphenol-induced, endothelium-dependent NO-mediated relaxation is due to the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of …
  1270. Red wine retards Abeta deposition and neuroinflammation in Alzheimer’s disease
  1271. Red wine, resveratrol, and Alzheimer’s disease
  1272. Redox chemistry of green tea polyphenols: therapeutic benefits in Neurodegenerative diseases
  1273. Reduction is the New Youth: The Effect of Polyphenols on Brain Aging and Diseases
  1274. Regulation of autophagy by polyphenols: Paving the road for treatment of neurodegeneration
  1275. Relationship between Wine Consumption and Alzheimer’s Disease
  1276. Relationship of Wine Consumption with Alzheimer’s Disease
  1277. Relationships of dietary patterns, foods, and micro-and macronutrients with Alzheimer’s disease and late-life cognitive disorders: a systematic review
  1278. Research Article Improvement of Learning and Memory by Morin, A flavonoid in Young and Aged Mice
  1279. Research of polyphenols with neuroprotective potential in a yeast model of degeneration
  1280. Restoration of stressor-induced calcium dysregulation and autophagy inhibition by polyphenol-rich açaí (Euterpe spp.) fruit pulp extracts in rodent brain cells in vitro
  1281. Resveratrol and Grape’s Extract-Loaded Solid Lipid Nanoparticles for the Treatment of Parkinson’s and Alzheimer’s Diseases
  1282. Resveratrol as a potential therapeutic candidate for the treatment and management of Alzheimer’s disease
  1283. Resveratrol—a boon for treating Alzheimer’s disease?
  1284. Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia
  1285. Reverse Alzheimer’s Disease Naturally: Alternative Treatments for dementia including Alzheimer’s Disease
  1286. Review of natural products on Parkinson’s disease pathology
  1287. Review of Traditional and Natural Methods of Treating Alzheimer’s Disease
  1288. REVIEW ON CURRENT TREATMENT STRATEGY IN Alzheimer’s DISEASE AND ROLE OF HERBS IN TREATING NEUROLOGICAL DISORDERS
  1289. Review on potential phytocompounds in drug development for Parkinson disease: a pharmacoinformatic approach
  1290. Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective
  1291. Rhodiola rosea L. and Alzheimer’s Disease: From Farm to Pharmacy
  1292. Rhodiola rosea L.-An evaluation of safety and efficacy in the context of a neurological disorder, Alzheimer Disease
  1293. Role of Acetylcholinesterase Inhibitors and Alzheimer Disease
  1294. Role of alpha-synuclein primary structure and oxidative stressin Parkinson’s disease pathology
  1295. Role of amyloid-β–metal interactions in Alzheimer’s disease
  1296. Role of flavonoids in Neurodegenerative Disorders with Special Emphasis on Tangeritin
  1297. Role of flavonoids in oxidative stress
  1298. ROLE OF HESPERETIN & PYRIDOXINE PROTECT IN THE NIGROSTRIATAL DOPAMINERGIC PROJECTION IN A NEUROTOXIN MODEL OF PARKINSON’S
  1299. Role of intestinal microbiota in the generation of polyphenol‐derived phenolic acid mediated attenuation of Alzheimer’s disease β‐amyloid oligomerization
  1300. Role of medicinal plants against Alzheimer’s disease
  1301. Role of medicinal plants in Neurodegenerative diseases with special emphasis to alzheimer’s
  1302. Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer’s disease
  1303. Role of Nutraceuticals in Alzheimer’s disease
  1304. Role of p38/MAPKs in Alzheimer’s disease: implications for amyloid beta toxicity targeted therapy
  1305. Role of plant polyphenols in Alzheimer’s disease
  1306. Role of plant-derived flavonoids and their mechanism in attenuation of Alzheimer’s and Parkinson’s diseases: An update of recent data
  1307. Role of polyphenols in cell death control
  1308. Role of Polyphenols in the prevention of neurodegeneration
  1309. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer’s and Parkinson’s diseases
  1310. Role of standardized grape polyphenol preparation as a novel treatment to improve synaptic plasticity through attenuation of features of metabolic syndrome in a …
  1311. Role of the APP non-amyloidogenic signaling pathway and targeting α-secretase as an alternative drug target for treatment of Alzheimer’s disease
  1312. Role of the Microbiome in polyphenol Metabolite-Mediated Attenuation of β-amyloid and tau Protein Misfolding in Alzheimer’s Disease
  1313. Roles of AMP-activated protein kinase in Alzheimer’s disease
  1314. Rosmarinic acid suppresses Alzheimer’s disease development by reducing amyloid β aggregation by increasing monoamine secretion
  1315. Roundoc Rx: Neurodegenerative Disease: Part 2—Top Herbs and Supplements for Addressing Alzheimer’s and Parkinson’s Disease
  1316. Rutin as a natural therapy for Alzheimer’s disease: Insights into its mechanisms of action
  1317. Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson’s disease
  1318. Screening and evaluation of natural compounds for therapeutic application in Alzheimer’s disease
  1319. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer’s disease and in other Neurodegenerative diseases
  1320. Secretase inhibitors for the treatment of Alzheimer’s disease: Long road ahead
  1321. Secretory phospholipase A2-IIA in Alzheimer’s disease and inflammatory responses in astrocytes
  1322. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
  1323. Separations with Raman Spectroscopy for Identification of Oxidatively Modified Components in Parkinson’s Disease
  1324. Serum concentrations of vitamin E and carotenoids are altered in Alzheimer’s disease: A case-control study
  1325. Several targets involved in Alzheimer’s disease amyloidogenesis are affected by morin and isoquercitrin
  1326. Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
  1327. Short-term dietary supplementation of blueberry polyphenolics: beneficial effects on aging brain performance and peripheral tissue function
  1328. Short-term dietary supplementation of blueberry polyphenolics: beneficial effects on aging brain performance and peripheral tissue function
  1329. Signal transduction in Alzheimer disease: p21‐activated kinase signaling requires C‐terminal cleavage of APP at Asp664
  1330. Signaling pathway cross talk in Alzheimer’s disease
  1331. Significant roles of neuroinflammation in Parkinson’s disease: therapeutic targets for PD prevention
  1332. Silymarin attenuated the amyloid β plaque burden and improved behavioral abnormalities in an Alzheimer’s disease mouse model
  1333. Silymarin’s inhibition and treatment effects for Alzheimer’s disease
  1334. Simple In Vivo Models of Alzheimer’s Disease
  1335. Simultaneous determination of phenolic compounds in Catharanthus roseus leaves by HPLC method
  1336. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases
  1337. Sir-2.1 mediated attenuation of α-synuclein expression by Alaskan bog blueberry polyphenols in a transgenic model of Caenorhabditis elegans
  1338. Sirtuins as novel targets for Alzheimer’s disease and other Neurodegenerative disorders: experimental and genetic evidence
  1339. Sirtuins in Alzheimer’s disease: SIRT2-related genophenotypes and implications for pharmacoepigenetics
  1340. Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues
  1341. Small molecule natural products and Alzheimer’s disease
  1342. Sophora Tomentosa Extract Prevents MPTP-Induced Parkinsonism in C57BL/6 Mice Via the Inhibition of GSK-3β Phosphorylation and Oxidative Stress
  1343. Spices And Herbs: An Essential Guide To Spice Up Your Health And Flavor Your Diet
  1344. ß-Amyloid and oxidative stress in the Pathogenesis of Alzheimer’s Disease
  1345. Stahl’s Illustrated Alzheimer’s Disease and Other Dementias
  1346. Statistical and Data Mining Methodologies for Behavioral Analysis in Transgenic Mouse Models of Alzheimer’s Disease: Parallels with Human AD Evaluation
  1347. Stem Cell Biology for Therapeutic Development in Parkinson’s Disease
  1348. STEM CELL-BASED THERAPY FOR Alzheimer’s DISEASE
  1349. Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer’s Disease
  1350. Strategies for Multi-target Directed Ligands: Application in Alzheimer’s Disease (AD) Therapeutics
  1351. Structural Analysis of Flavonoid/Drug Target Complexes: Natural Products as Lead Compounds for Drug Development
  1352. Structural Elucidation of Novel Phenolic Glycosides in Cimicifugae Rhizoma by Structure-based Chemical Screening using LC-NMR and LC-UV-MS
  1353. Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity
  1354. Structure-activity relationships of flavonoids
  1355. Structure–activity relationships of acetylated flavone glycosides from Galeopsis ladanum L.(Lamiaceae)
  1356. Studies on Amyloid Beta Peptide Aggregation and Its Modulation by Garlic Components: Relevance to Alzheimer’s Disease
  1357. Studies on the Leaves of Punica Granatum Linn. and its Invitro Inhibition of Ache for Potential Use in Alzheimer’s Treatment
  1358. Study of oxidative stress and Alzheimer’s disease in transgenic mice and pharmacological agents to counteract nutritional deficiency
  1359. Study of Possible neuroprotective Effects of Certain Drugs on Experimentally Induced Parkinson’s Disease in Rats
  1360. Study on neuroprotective capacity of key flavonoids of ampelopsis grossedentata
  1361. Sub-critical solvent extraction of flavonoid-rich grape by-products
  1362. Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer’s Disease: A Systematic Review
  1363. Supplementation with vitamins E plus C or soy isoflavones in ovariectomized rats: effect on the activities of Na+, K+-ATPase and cholinesterases
  1364. Suppression of presymptomatic oxidative stress and inflammation in neurodegeneration by grape-derived polyphenols
  1365. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity
  1366. Sweet Cherry Phenolic Compounds: Identification, Characterization, and Health Benefits
  1367. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease
  1368. Synergistic action of melatonin in combination with Anti-Parkinsonian drugs in experimental model of parkinson s disease
  1369. Synergistic antioxidant action of vitamin E and rutin SNEDDS in ameliorating oxidative stress in a Parkinson’s disease model
  1370. Synergistic Effect of Selected Hydroxy Cinnamic Acid Derivative (HCA) With Rivastigmine in Dementia
  1371. Synergistic neuroprotective effects of Withania somnifera with specific dietary derived polyphenols
  1372. Synergistic properties of bioavailable phenolic compounds from olive oil: electron transfer and neuroprotective properties
  1373. Synthesis and antioxidant activity of phenolic amides
  1374. Synthesis and biological evaluation of novel homoisoflavonoids for retinal neovascularization
  1375. Synthesis and Development of BACE 1 Inhibitor for Alzheimer’s Diseases from Medicinal Plants
  1376. Synthesis and evaluation of neuroprotective selenoflavanones
  1377. Synthesis of Isooctyl Phenol Analogs from Insect-Flower
  1378. Synthesis of phenolic amides and evaluation of their antioxidant and anti-inflammatory activity in vitro and in vivo
  1379. Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson’s disease
  1380. T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer’s disease: potential pools of new biomarkers
  1381. Target-based selection of flavonoids for Neurodegenerative disorders
  1382. Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
  1383. Targeting dysregulation of brain iron homeostasis in Parkinson’s disease by iron chelators
  1384. Targeting ERK signaling pathway by polyphenols as novel therapeutic strategy for neurodegeneration
  1385. Targeting Inflammatory Pathways in Alzheimer’s Disease: A Focus on Natural Products and Phytomedicines
  1386. Targeting miRNAs by polyphenols: novel therapeutic strategy for aging
  1387. Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
  1388. Targeting NADPH Oxidase and Phospholipases A2 in Alzheimer’s Disease
  1389. Targeting Parkinson’s-tyrosine hydroxylase and oxidative stress as points of interventions
  1390. Targeting the Nrf2/amyloid-beta liaison in Alzheimer’s disease: A rational approach
  1391. Targeting the progression of Parkinson’s disease
  1392. Targeting α-synuclein aggregation for Parkinson’s disease treatment
  1393. Targeting α-Synuclein as a Parkinson’s Disease Therapeutic
  1394. Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
  1395. Tea and Parkinson’s disease: Constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits
  1396. Tea flavonoids and their effect on chronic inflammation induced in Trypanosoma brucei brucei infected mice
  1397. Tea-Derived Polyphenols and Stilbenes on Amyloid Neurotoxicity
  1398. The ability of three African herbal remedies to offer protection against an in vitro model of Parkinson’s disease
  1399. The action of polyphenols in diabetes mellitus and Alzheimer’s disease: A common agent for overlapping pathologies
  1400. The Alzheimer’s Prevention Cookbook: 100 Recipes to Boost Brain Health
  1401. The amyloid beta peptide: a chemist’s perspective. Role in Alzheimer’s and fibrillization
  1402. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal
  1403. The anti-amyloidogenic effect is exerted against Alzheimer’s β-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure
  1404. The Antimicrobial Activity Mechanism of Sophoraflavanone B against Methicillin-Resistant Staphylococcus aureus
  1405. The antioxidant properties of 4–quinolones compared to structurally related flavonoids
  1406. The Association Between Dietary flavonoid Intake and Chronic Obstructive Pulmonary Disease, Systemic Inflammation, and Comorbidity Burden
  1407. The beneficial and deleterious role of dietary polyphenols on chronic degenerative diseases by regulating gene expression
  1408. The beneficial effects of dietary flavonoids: Sources, bioavailability and biological functions
  1409. The beneficial effects of fruit polyphenols on brain aging
  1410. The beneficial role of Naringin-a citrus bioflavonoid, against oxidative stress-induced neurobehavioral disorders and cognitive dysfunction in rodents: A systematic …
  1411. THE BENEFITS OF RESVERATROL WITH POLYPHENOLS IN Parkinson’s DISEASE WITH Alzheimer’s CHANGES
  1412. The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson’s disease
  1413. The cascade of oxidative stress and tau protein autophagic dysfunction in Alzheimer’s disease
  1414. The Change of Neurotransmitters in Plasma of dementia Patients after Aromatherapy.
  1415. The Crocus sativus compounds trans-crocin 4 and trans-crocetin modulate the amyloidogenic pathway and tau misprocessing in Alzheimer disease neuronal cell …
  1416. The development of preventives and therapeutics for Alzheimer’s disease that inhibit the formation of β-amyloid fibrils (fAβ), as well as destabilize preformed fAβ
  1417. The Effect of Essential Oil on Plasma Level of 5-HT in dementia Patients
  1418. The effect of Ginkgo biloba extract on parkinsonisminduced biochemical changes in brain of irradiated rats
  1419. The effect of green tea consumption on oxidative stress markers and cognitive function in patients with Alzheimer’s disease: A prospective intervention study
  1420. The effect of polyphenols on protein degradation pathways: implications for neuroprotection
  1421. The effect of Scutellaria baicalensis stem-leaf flavonoids on spatial learning and memory in chronic cerebral ischemia-induced vascular dementia of rats
  1422. The effects of flavonoid and other polyphenol consumption on cognitive performance: a systematic research review of human experimental and epidemiological …
  1423. The effects of the flavonoid baicalein and osmolytes on the Mg 2+ accelerated aggregation/fibrillation of carboxymethylated bovine 1SS-α-lactalbumin
  1424. The Effects of the Green Tea polyphenol Epigallocatechin Gallate on the Central Nervous, Endocrine, and Innate Immune Systems
  1425. The epidemiology of Parkinson’s disease: risk factors and prevention
  1426. The flavanol (−)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against …
  1427. The flavone luteolin improves central nervous system disorders by different mechanisms: a review
  1428. The flavonoid baicalein promotes NMDA receptor‐dependent long‐term potentiation and enhances memory
  1429. The flavonoid Derivative 2-(4′ Benzyloxyphenyl)-3-hydroxy-chromen-4-one Protects Against Aβ42-Induced Neurodegeneration in Transgenic Drosophila: Insights …
  1430. The flavonoid quercetin ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model …
  1431. The flavonoids ameliorates: protective mechanisms in Neurodegenerative diseases
  1432. The GC-MS analyses of the n-hexane extract of Nitraria schoberi L., its total phenolics and in vitro antioxidant activity
  1433. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide‐induced toxicity: involvement of its flavonoid constituents and protein …
  1434. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide‐induced toxicity: involvement of its flavonoid constituents and protein …
  1435. The Ginkgo biloba extract EGb 761® and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex
  1436. The gut microbiota links dietary polyphenols with management of psychiatric mood disorders
  1437. The Healthy Mind Cookbook: Big-flavor Recipes to Enhance Brain Function, Mood, Memory, and Mental Clarity
  1438. The immunomodulatory and anti-inflammatory role of polyphenols
  1439. The impact of flavonoids on memory: physiological and molecular considerations
  1440. The impact of fruit flavonoids on memory and cognition
  1441. The impact of gastrointestinal modifications, blood-brain barrier transport, and intracellular metabolism on polyphenol bioavailability: an overview
  1442. The influence of beverage composition on delivery of phenolic compounds from coffee and tea
  1443. The influence of common free radicals and antioxidants on development of Alzheimer’s Disease
  1444. The influence of oxidative stress in Alzheimer’s disease-possible beneficial relevance of the antioxidants from wheatgrass juice. Review Article
  1445. The influence of plant extracts on Ȼ Amyloid induced pathologies in an APP/PS1 mouse model of Alzheimer’s disease
  1446. The interactions of flavonoids within neuronal signalling pathways
  1447. The mechanisms of action of flavonoids in the brain: direct versus indirect effects
  1448. The medicinal chemistry of natural and semisynthetic compounds against Parkinson’s and Huntington’s diseases
  1449. The Mind Diet: A Scientific Approach to Enhancing Brain Function and Helping Prevent Alzheimer’s and Dementia
  1450. The molecular basis of the prevention of Alzheimer’s disease through healthy nutrition
  1451. The molecular basis of working mechanism of natural polyphenolic antioxidants
  1452. The n-Butanol Fraction and Rutin from Tartary Buckwheat Improve Cognition and Memory in an In Vivo Model of Amyloid-β-Induced Alzheimer’s Disease
  1453. The neuroprotective effect and action mechanism of polyphenols in diabetes mellitus-related cognitive dysfunction
  1454. The neuroprotective effects of cocoa flavanol and its influence on cognitive performance
  1455. The neuroprotective potential of flavonoids: a multiplicity of effects
  1456. The neuroprotective potential of phenolic-enriched fractions from four Juniperus species found in Portugal
  1457. The Nrf2/HO-1 Axis as Targets for Flavanones: Neuroprotection by Pinocembrin, Naringenin, and Eriodictyol
  1458. The Nutritional Components of Beer and Its Relationship with Neurodegeneration and Alzheimer’s Disease
  1459. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer’s disease
  1460. The oxidative stress hypothesis in Alzheimer’s disease
  1461. The potential of flavonoids for the treatment of Neurodegenerative diseases
  1462. The potential role of dietary polyphenols in Parkinson’s disease
  1463. The prenylflavonoid xanthohumol reduces Alzheimer-like changes and modulates multiple pathogenic molecular pathways in the neuro2a/APPswe cell …
  1464. The present and future of pharmacotherapy of Alzheimer’s disease: A comprehensive review
  1465. The protective role of plant biophenols in mechanisms of Alzheimer’s disease
  1466. The relevance body mass index on the oxidative stress status of Alzheimer’s disease pathology
  1467. The role of dietary coconut for the prevention and treatment of Alzheimer’s disease: potential mechanisms of action
  1468. The Role of HIV-1 Proteins in Alzheimer’s Disease Pathology
  1469. The role of iron-induced fibrin in the pathogenesis of Alzheimer’s disease and the protective role of magnesium
  1470. The role of lifestyle factors in cognitive aging and dementia
  1471. The role of lipids and membranes in the pathogenesis of Alzheimer’s disease: a comprehensive view
  1472. The role of natural products in Alzheimer’s and Parkinson’s disease
  1473. The role of natural products in the discovery of new drug candidates for the treatment of Neurodegenerative disorders II: Alzheimer’s disease
  1474. The role of nutrient-based epigenetic changes in buffering against stress, aging, and Alzheimer’s disease
  1475. The role of nutrition in the prevention and treatment of dementia
  1476. The Role of oxidative stress and Cholesterol in Animal Models of Alzheimer’s Disease
  1477. The role of phenolic OH groups of flavonoid compounds with H-bond formation ability to suppress amyloid mature fibrils by destabilizing β-sheet conformation …
  1478. The role of phytochemicals in the treatment and prevention of dementia
  1479. The role of polyphenolic antioxidants in health, disease, and aging
  1480. The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer’s disease
  1481. The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: a mini review
  1482. The role of rutin and diosmin, two citrus polyhydroxyflavones in disease prevention and treatment
  1483. The role of the ubiquitin proteasome system in Alzheimer’s disease
  1484. The Safe and Effective Applications of Essential Oils in Alzheimer’s Dementia
  1485. The science of cocoa flavanols: bioavailability, emerging evidence, and proposed mechanisms
  1486. The Simplicity of dementia A Guide for Family and Carers
  1487. The Structural Hybrids of Acetylcholines-terase Inhibitors in the Treatment of Alzheimer’s Disease: A Review
  1488. The therapeutic potential of rosemary (Rosmarinus officinalis) diterpenes for Alzheimer’s disease
  1489. The Therapeutic Role of Turmeric in Treatment and Prevention of Alzheimer’s Disease
  1490. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies
  1491. The Treatment of Brain Inflammation in Alzheimer’s Disease. Can Traditional Medicines Help?
  1492. The use of cell-free systems to characterize Parkinson’s disease-related gene products
  1493. The use of flavonoids in central nervous system disorders
  1494. The use of herbal medicine in Alzheimer’s disease—a systematic review
  1495. The Use of herbal supplements on minimizing the clinical manifestations of Alzheimer’s disease
  1496. The Use of Polyphenols for the Treatment of Alzheimer’s Disease
  1497. Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?
  1498. Therapeutic agents in Alzheimer’s disease through a multi-targetdirected ligands strategy: recent progress based on tacrine core
  1499. Therapeutic approaches to Alzheimer’s disease through stimulating of non-amyloidogenic processing of amyloid precursor protein
  1500. Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson’s disease
  1501. Therapeutic effect of modulating TREM-1 via anti-inflammation and autophagy in Parkinson’s disease
  1502. Therapeutic effects of Cyperus rotundus rhizome extract on memory impairment, neurogenesis and mitochondria in beta-amyloid rat model of Alzheimer’s disease
  1503. Therapeutic impact of grape leaves polyphenols on certain biochemical and neurological markers in AlCl3-induced Alzheimer’s disease
  1504. Therapeutic implications of anti-inflammatory natural products in Alzheimer’s disease
  1505. Therapeutic interventions for the suppression of Alzheimer’s disease: quest for a remedy
  1506. Therapeutic potential of baicalein in Alzheimer’s disease and Parkinson’s disease
  1507. Therapeutic Potential Of Catechins And Derivatives For The Prevention Of Alzheimer’s
  1508. Therapeutic Potential Of Catechins And Derivatives For The Prevention Of Alzheimer’s Disease
  1509. Therapeutic potential of luteolin in transgenic Drosophila model of Alzheimer’s disease
  1510. Therapeutic potential of natural products in Parkinson’s disease
  1511. Therapeutic Potential of Polyphenols from Epilobium Angustifolium (Fireweed)
  1512. Therapeutic Potential of Polyphenols in Parkinson’s Disease
  1513. Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview
  1514. Therapeutic potentials of microalgae in the treatment of Alzheimer’s disease
  1515. Therapeutic potentials of plant iridoids in Alzheimer’s and Parkinson’s diseases: A review
  1516. Therapeutic role of sirtuins in Neurodegenerative disease and their modulation by polyphenols
  1517. Therapeutic strategies targeting amyloid-β in Alzheimer’s disease
  1518. Therapeutics of Alzheimer’s disease: Past, present and future
  1519. Therapies for Parkinson’s diseases: alternatives to current pharmacological interventions
  1520. Therapies for prevention and treatment of Alzheimer’s disease
  1521. Thymus pulegioides L. as a rich source of antioxidant, anti-proliferative and neuroprotective phenolic compounds
  1522. Tissue injury by reactive oxygen species and the protective effects of flavonoids
  1523. To Study The Ameliorative Effect Of Hydroalcholic Extract Of Caryota urens (Arecaceae) On Streptozotocin Induced Alzheimer’s Model In Mice
  1524. Tomato (Lycopersicon esculentum) seeds: new flavonols and cytotoxic effect
  1525. Tools of the trade: investigations into design strategies of small molecules to target components in Alzheimer’s disease
  1526. Total and specific polyphenol intakes in midlife are associated with cognitive function measured 13 years later
  1527. Total Phenolic and flavonoid Content and Biological Activities of Extracts and Isolated Compounds of Cytisus villosus Pourr.
  1528. Total Phenolic, Flavonoid, Fatty Acid Contents and Cytotoxic, Antioxidant, and Antimicrobial Activities of Hedysarum aucheri
  1529. Total Synthesis of an C-CH2-C Linked Ochnaflavone
  1530. Total Synthesis of Ochnaflavone Analogs Having CNH-C and CSC Linkages
  1531. Total Synthesis of Ochnaflavone, A Potent Plant-originated Biflavonoid with Anti-inflammatory Activity
  1532. Towards a bioinformatics analysis of anti-Alzheimer’s herbal medicines from a target network perspective
  1533. Toxic exposure and life style factors on ageing brain Neurodegenerative disease, Alzheimer’s and Parkinson’s: Role of natural antioxidants to ameliorate the condition
  1534. Traditional and modern medicine harmonizing the two approaches in the treatment of neurodegeneration (Alzheimer’s disease-AD)
  1535. Traditional Chinese medicines and Alzheimer’s disease
  1536. Traditional Medicine in the Treatment of dementia and Alzheimer’s Disease
  1537. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
  1538. Transthyretin chemical chaperoning by flavonoids: Structure–activity insights towards the design of potent amyloidosis inhibitors
  1539. Treatment of Alzheimer Disease with Phytochemicals Other Than Curcumin
  1540. Treatment of inflammatory bowel disease via green tea polyphenols: Possible application and protective approaches
  1541. Troxerutin exerts neuroprotection in 6-hydroxydopamine lesion rat model of Parkinson’s disease: Possible involvement of PI3K/ERβ signaling
  1542. Type 2 diabetes mellitus and Alzheimer’s disease: bridging the pathophysiology and management
  1543. Tyrosol Reduces Amyloid-β Oligomer Neurotoxicity and Alleviates Synaptic, Oxidative, and Cognitive Disturbances in Alzheimer’s Disease Model Mice
  1544. Ulmosides A: flavonoid 6-C-glycosides from Ulmus wallichiana attenuates lipopolysacchride induced oxidative stress, apoptosis and neuronal death
  1545. Understanding Alzheimer’s Disease and Other Dementias
  1546. UNDERSTANDING PHYTOTHERAPY OF Alzheimer’s DISEASE: LAST DECADE AND COMING FUTURE
  1547. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and Neurodegenerative diseases
  1548. Unique properties of polyphenol stilbenes in the brain: more than direct antioxidant actions; gene/protein regulatory activity
  1549. Use of Herbal Products/Alternative Medicines in Neurodegenerative Diseases (Alzheimer’s Disease and Parkinson’s Disease)
  1550. Validation of neuroprotective action of a commercially available formulation of olive polyphenols in a zebra-fish model vis-a-vis pure hydroxytyrosol
  1551. Vanillin attenuated behavioural impairments, neurochemical deficts, oxidative stress and apoptosis against rotenone induced rat model of Parkinson’s disease
  1552. Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer’s disease: a new approach to therapy
  1553. VISCUM ALBUM ENHANCES BLOOD SERUM BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) LEVEL IN EXPERIMENTAL MODEL OF Alzheimer’s …
  1554. Walnut supplementation in the diet reduces oxidative damage and improves antioxidant status in transgenic mouse model of Alzheimer’s disease
  1555. What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research
  1556. Whole-food diet worsened cognitive dysfunction in an Alzheimer’s disease mouse model
  1557. Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson’s and Alzheimer’s disorders?
  1558. Wine consumption, cognitive function and dementias–A relationship?
  1559. Wine flavonoids in health and disease prevention
  1560. Wine phenolics
  1561. Wine Polyphenols and Neurodegenerative Diseases: An Update on the Molecular Mechanisms Underpinning Their Protective Effects
  1562. Wine polyphenols: potential agents in neuroprotection
  1563. Wine-Derived Phenolic Metabolites in the Digestive and Brain Function
  1564. Withanolides: biologically active constituents in the treatment of Alzheimer’s disease
  1565. Xanthone and flavone derivatives as dual agents with acetylcholinesterase inhibition and antioxidant activity as potential anti-alzheimer agents
  1566. Xenobiotic metabolism and berry flavonoid transport across the blood− brain barrier
  1567. Zingiber officinale and Alzheimer’s disease: evidences and mechanisms
  1568. α-Synuclein Aggregation and Parkinson’s Disease
  1569. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson’s disease
  1570. α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis
  1571. α-Synuclein misfolding and Parkinson’s disease
  1572. α‐Synuclein oligomers and clinical implications for Parkinson disease
  1573. β-Synuclein Assembly as a Therapeutic Target of Parkinson’s Disease and Related Disorders
  1574. … -DAD Fingerprinting Analysis, Antioxidant Activity of Phenolic Extracts from Blighia sapida Bark and Its Inhibition of Cholinergic Enzymes Linked to Alzheimer’s …
  1575. … -rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson’s disease
  1576. … , Biological Evaluation And Molecular Modeling Studies Of Novel Multifunctional neuroprotective Drugs For The Treatment Of Parkinson’s Disease: An Effort …
  1577. … , α-Glucosidase, Pancreatic Lipase, Acetyl-and Butyrylcholinesterase Inhibition Activity of Chaenomeles Fruits Determined by Polyphenols and other Chemical …
  1578. … acid and E. resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson’s disease: a pharmacoinformatics study
  1579. … and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia
  1580. … and antioxidant potentials of a medicinal plant Abroma augusta: Implications for the alternative treatment therapy of cognitive deficits in Alzheimer’s disease
  1581. … and their acetyl cholinesterase inhibitory and antioxidant activities from leaves of Acanthopanax henryi: potential complementary source against Alzheimer’s disease
  1582. … bovine 1SS-alpha-lactalbumin as a model for disease-related amyloidogenic polypeptides: The effects of osmolytes, the flavonoid baicalein, and the GroEL …
  1583. … chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: A Preliminary anti- Alzheimer’s study
  1584. … chrysin loaded solid lipid nanoparticles against Amyloid β25–35 induced oxidative stress in rat hippocampal region: An efficient formulation approach for Alzheimer’s …
  1585. … composition, antioxidant potential and in vitro inhibitory activity of leaves and acorns of Quercus suber on key enzymes relevant for hyperglycemia and Alzheimer’s …
  1586. … effects of inhaled Hypericum scabrum L.(Hypericaceae) essential oil against scopolamine-induced Alzheimer’s type dementia/Scopolamine ile oluşturulan …
  1587. … effects of water extract of propolis on dopaminergic neurons, brain derived neurotrophic factor, and stress oxidative Factors in the rat model of Parkinson’s …
  1588. … efficiency of co-administration of Ginkgo biloba and Trifolium pretense against sodium arsenite-induced neurotoxicity and dementia in different regions of brain and …
  1589. … fingerprint analysis, antioxidant properties, and inhibition of cholinergic enzymes (acetylcholinesterase and butyrylcholinesterase) of phenolic extracts from Irvingia …
  1590. … flavonoid attenuates cognitive dysfunction and neuronal loss associated with amyloid β (25-35)-induced oxidative stress: an experimental model of Alzheimer’s …
  1591. … for the Therapy of Proteinopathies Underlying the Neurodegenerative Conditions: Protein Misfolding and Fibrillization in Alzheimer’s Disease and Parkinson’s …
  1592. … from sesame cake reduce oxidative stress and amyloid-β-induced toxicity by upregulation of SKN-1 in a transgenic Caenorhabditis elegans model of Alzheimer’s …
  1593. … Impairment Attenuating Effect of Phenolic Compound Rich Fraction of Trianthema portulacastrum in Scopolamine Induced Alzheimer’s Disease Like Condition
  1594. … IN THE PREVENTION AND MANAGEMENT OF AGE RELATED Neurodegenerative DISORDERS WITH SPECIAL REFERENCE TO SENILE DEMENTIA
  1595. … in tumor necrosis factor like weak inhibitor of apoptosis induced dopaminergic neuronal cell death and microglial activation in invitro and in vivo models of Parkinson …
  1596. … INDUCES PKD1 ACTIVATION AND PROTECTS DOPAMINERGIC NEURONS IN CELL CULTURE AND MITOPARK ANIMAL MODELS OF Parkinson’s …
  1597. … inhibitory potential and estimation of alkaloids (lycorine and galanthamine) from Crinum species: an important source of anticancer and anti-Alzheimer drug
  1598. … KATEKIN GAMBIR TERHADAP KADAR BACE-1 DAN BETA AMYLOID 42 CAIRAN SEREBROSPINAL PADA TIKUS Sprague dawley MODEL ALZHEIMER
  1599. … modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s …
  1600. … mombim L.(Anacardiaceae): Chemical fingerprints, inhibitory activities, and molecular docking on key enzymes relevant to erectile dysfunction and Alzheimer’s …
  1601. … neurorescue against Aβ toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate
  1602. … of crude extracts, subsequent fractions, saponins and flavonoids of atriplex laciniata L.: potential effectiveness in Alzheimer’s and other neurological …
  1603. … of diagnostic agents, self-assembly inhibitors, and hippocampal transcriptional changes specific to amyloid β-proteinassemblies linked to Alzheimer’s disease
  1604. … of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer’s disease mice model
  1605. … of flavonoids, baicalein, and daidzein in estrogenic and neuroprotective effects: a development of potential health products and therapeutic drugs against Alzheimer’s …
  1606. … of hydroalcoholic extract of Ziziphora clinopodioides L. on spatial memory and neuronal density of hippocampal CA1 region in rats with sporadic Alzheimer’s …
  1607. … of iron‐regulated amyloid precursor protein and β‐amyloid peptide by (–)‐epigallocatechin‐3‐gallate in cell cultures: implications for iron chelation in Alzheimer’s …
  1608. … of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology …
  1609. … OF THE POSSIBLE ANTIOXIDANT EFFECTS OF PEGANUM HARMALA AND GINKGO BILOBA IN AMELIORATING Alzheimer’s DISEASE IN RAT MODEL
  1610. … OF ΑLPHA-YNUCLEIN SEEDED NUCLEATION-DEPENDENT AGGREGATION AND TOXICITY AS A POTENTIAL THERAPEUTIC STRATEGY FOR Parkinson’s …
  1611. … performance in relation to urinary anthocyanins and their flavonoid-based products following blueberry supplementation in older adults at risk for dementia
  1612. … pluricaulis (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAPτ) induced neurotoxicity in Alzheimer’s disease Drosophila model
  1613. … pyrroloquinolinequinone-containing dietary formulation on motor deficiency, cognitive decline and mitochondrial dysfunction in a mouse model of Alzheimer’s …
  1614. … STRESS, NEUROINFLAMMATION AND NEURODEGENERATION AGAINST LIPOPOLYSACCHARIDE-INDUCED Alzheimer’s DISEASE VIA JNK-3 AND …
  1615. … the brain functions by bitter (Vernonia amygdalina) and water bitter (Struchium sparganophora) leaves extracts: comparison of phenolic constituents versus nootropic …
  1616. … the functional diversity of flavonoids derived from Chinese Materia Medica: Drug developments for the prevention of Alzheimer’s disease and osteoporosis
  1617. … with HPLC-FTMS of exogenous and endogenous chemicals susceptible to the administration of chotosan in an animal model of type 2 diabetes-induced dementia
  1618. “A GREAT PERTURBATION IN NATURE”-Parkinson’s DISEASE AND SLEEP DISORDERS–
  1619. “Polyphenolic-food” Effects on Brain Health (Human Data review)
  1620. 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine is a potent neurotoxin: Gamma-tocopherol recuperate behavior, dopamine, and oxidative stress on Parkinsonic …
  1621. 10. neuroprotective effects of oxyresveratrol from fruit against neurodegeneration in Alzheimer’s disease
  1622. 15 Alzheimer’s Disease and Other Forms of Dementia
  1623. 15 Apple Phenolics and Alzheimer’s Disease
  1624. 15 Botanical Phenolics and Neurodegeneration
  1625. 15 Dietary flavonoids as neuroprotective Agents
  1626. 15 Green Tea Flavan-3-ols
  1627. 16 Actions of Bioactive Phytochemicals in Cell Function and Alzheimer’s Disease Pathology
  1628. 17 Effects of flavonoids on Cognitive Performance
  1629. 19 Natural Phenolics and Metal Metabolism in Neurodegenerative Diseases
  1630. 19 The neuroprotective Capacity of Achyrocline satureioides (Lam) DC and Its Flavonoids
  1631. 2 Direct Evaluation of Alzheimer’s Disease-Specific oxidative stress with Multiphoton Microscopy
  1632. 3, 5, 4′-trihydroxy-6, 7, 3′-trimethoxyflavone protects against beta amyloid-induced neurotoxicity through antioxidative activity and interference with cell …
  1633. 4 Coffee and Alzheimer’s Disease: Animal and Cellular Evidence
  1634. 6 neuroprotective Mechanisms: oxidative stress as a Target for neuroprotective Therapies in Alzheimer’s and Parkinson’s
  1635. 6-Shogaol has neuroprotective Effects in Parkinson’s Disease Model
  1636. 7, 8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders
  1637. 7, 8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders
  1638. 8 Neuroprotection by Dietary and Citrus Flavonoids
  1639. A blueberry-enriched diet provides cellular protection against oxidative stress and reduces a kainate-induced learning impairment in rats
  1640. A botanical containing freeze dried açai pulp promotes healthy aging and reduces oxidative damage in sod1 knockdown flies
  1641. A brief review on the neuroprotective mechanisms of vitexin
  1642. A Close Look at Echium amoenum Processing, Neuroactive Components, and Effects on Neuropsychiatric Disorders
  1643. A cocoa peptide protects Caenorhabditis elegans from oxidative stress and β-amyloid peptide toxicity
  1644. A Combination of Green Tea Extract and l-Theanine Improves Memory and Attention in Subjects with Mild Cognitive Impairment: A Double-Blind Placebo-Controlled …
  1645. A comparative study of the in vitro enzyme inhibitory and antioxidant activities of Butea monosperma (Lam.) Taub. and Sesbania grandiflora (L.) Poiret from Pakistan …
  1646. A comparative study on the antioxidant and immunomodulatory properties of curcumin conjugated gold nanospheres and free curcumin
  1647. A comparative thin layer chromatography study of different brands of five herbal remedies
  1648. A Comparison of Inhibitory Effects on Catecholamine Secretion between CGP42112 and CGP42112 plus PD123319
  1649. A comparison of the efficacy and tolerability of interferon-beta (INFb) products used as initial or follow-up therapy for the treatment of relapsing multiple sclerosis …
  1650. A Comprehensive Insight on the Health Benefits and Phytoconstituents of Camellia sinensis and Recent Approaches for Its Quality Control
  1651. A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases
  1652. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies
  1653. A crosssectional study of ethnopharmacology in the Noakhali district of Bangladesh and exploring potential ocular immunostimulatory activity of the medicinal …
  1654. A current perspective on the inhibition of cholinesterase by natural and synthetic inhibitors
  1655. A current update on phytochemistry, pharmacology and herb–drug interactions of Hypericum perforatum
  1656. A diet for dopaminergic neurons?
  1657. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of …
  1658. A life-course contribution of nutrition to future cognitive decline
  1659. A Mini Review on the Protective Effect of Lignans for the Treatment of Neurodegenerative Disorders
  1660. A mixture of fucoxanthin and punicic acid prevents obesity in high-fat diet-induced obese mice
  1661. A New Therapeutic Concept of LMT356 for Stroke Therapy: Extension of the Thrombolytic Time Window of tPA
  1662. A Novel Approach towards Nutraceuticals and Biomedical Applications
  1663. A Novel neuroprotective and Antioxidative Efficacy of a Unique Combination of Standardized Huperzia serrata, Convolvulus pluricaulis and Celastrus …
  1664. A pharmacognostic and pharmacological review on Vigna aconitifolia (Moth bean)
  1665. A Pharmacological Review of Bioactive Constituents of Paeonia lactiflora Pallas and Paeonia veitchii Lynch
  1666. A Pilot Study to Evaluate Chemopreventive Effects of Blueberry (Vaccinium spp.)
  1667. A Polysaccharide Produced by a New Streptomyces Strain Modulates Immunological Activity in RAW264. 7 Cells
  1668. A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects
  1669. A possible role for π-stacking in the self-assembly of amyloid fibrils
  1670. A potential alternative against Neurodegenerative diseases: Phytodrugs
  1671. A Potential Natural Product Combination Targeting Memory Disorders
  1672. A randomized controlled trial investigating the effect of Pycnogenol and Bacopa CDRI08 herbal medicines on cognitive, cardiovascular, and biochemical …
  1673. A redox-active, compact molecule for cross-linking amyloidogenic peptides into nontoxic, off-pathway aggregates: in vitro and in vivo efficacy and molecular …
  1674. A refined concept: α-synuclein dysregulation disease
  1675. A review of dietary Ziziphus jujuba fruit (Jujube): developing health food supplements for brain protection
  1676. A review of Neuropharmacology Effects of Nigella sativa and Its Main Component, Thymoquinone
  1677. A review of neuroprotective agents
  1678. A Review of neuroprotective Agents
  1679. A review of some medicinal plants used for nervous disorders
  1680. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to Neurodegenerative processes
  1681. A review of the medicinal properties and applications of Pycnanthus angolensis (Welw) Warb
  1682. A review of the pharmacology and toxicology of aucubin
  1683. A review of the role of green tea (Camellia sinensis) in antiphotoaging, stress resistance, neuroprotection, and autophagy
  1684. A review of therapeutic effects of curcumin
  1685. A review of three commonly used herbs which enhance memory and new evidences which show their combination could improve memory in young animals
  1686. A review on ethnomedicinal, phytochemical, and pharmacological significance of Terminalia sericea Burch. Ex DC.
  1687. A review on medicinal importance, pharmacological activity and toxicology of ”Nutraceuticals”
  1688. A review on medicinal properties of saffron toward major diseases
  1689. A Review on Natural Antioxidants
  1690. A review on natural memory enhancers (Nootropics)
  1691. A Review on Neuronutrition
  1692. A review on nutraceuticals: classification and its role in various diseases
  1693. A Review on Pharmaceutically Important Medicinal plant: Bacopa monnieri
  1694. A Review on Phytochemistry and Pharmacology of Otostegia persica (Burm. f.) Boiss.
  1695. A review on possible therapeutic effect of Nigella sativa and thymoquinone in Neurodegenerative diseases
  1696. A review on spikenard (Nardostachys jatamansi DC.)-an ‘endangered’essential herb of India
  1697. A review on the phytopharmacological studies of the genus Polygala
  1698. A review on the possible neuroprotective effects of Moringa oleifera leaf extract
  1699. A Review on Therapeutic Potentials of Crocetin-A Carotenoid Derived from Saffron
  1700. A review on therapeutic potentials of Trigonella foenum graecum (fenugreek) and its chemical constituents in neurological disorders: Complementary roles to its …
  1701. A review on traditional uses, phytochemistry and pharmacology of Eclipta prostrata (L.) L.
  1702. A review study on medicinal plants affecting amnesia through cholinergic system
  1703. A Role for Activated Microglia and Peroxynitrite in Lewy Body Diseases–Implications for Prevention and Control
  1704. A Role for Orexin Neuron Activity in Cytotoxic Chemotherapy-Induced Fatigue
  1705. A Role of Gallic Acid in Oxidative Damage Diseases: A Comprehensive Review
  1706. A simple and efficient HPLC method for quantitative analysis of Gingkolides extracted from Ginkgonis Semen
  1707. A Splicing Variant of AIMP2 as a Therapeutic Controller for Neurodegenerative Diseases
  1708. A status review on the medicinal properties of essential oils
  1709. A STUDY ON ANTI-INFLANNATORY AND neuroprotective EFFECTS OS COSTUNOLIDE ON LIPOPOLYSACCHARIDE ACTIVATED MURINE BRAIN …
  1710. A STUDY ON CNS EFFECTS OF MILK EXTRACT OF NUTS OF SEMECARPUS ANACARDIUM. LINN,(ANACARDIACEAE).
  1711. A study on nephroprotectiveness and pharmacokinetic properties of selected nutraceuticals and evaluation of chronic renal failure inducing model for their …
  1712. A Synthetic Snake-Venom-Based Tripeptide Protects PC12 Cells from the Neurotoxicity of Acrolein by Improving Axonal Plasticity and Bioenergetics
  1713. A systematic and comprehensive review on Withania somnifera (L.) dunal-an indian ginseng
  1714. A systematic Approach to Evaluate Herb-drug Interaction Mechanisms: Investigation of a Purified Ginseng Extracts
  1715. A systematic overview of the scientific literature on the association between Mediterranean Diet and the Stroke prevention
  1716. A systematic review on Piper longum L.: Bridging traditional knowledge and pharmacological evidence for future translational research
  1717. A systematic review on the vocational pharmacy education and pharmacists’ role in the Singapore’s healthcare system
  1718. A therapeutic connection between dietary phytochemicals and ATP synthase
  1719. A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds
  1720. AARP Prescription for Drug Alternatives: All Natural Options for Better Health without the Side Effects
  1721. AARP The Immortality Edge: Realize the Secrets of Your Telomeres for a Longer, Healthier Life
  1722. ABC transporters and drug efflux at the blood-brain barrier
  1723. Açaí: An Extraordinary Antioxidant-Rich Palm Fruit
  1724. Acanthus ebracteatus leaf extract provides neuronal cell protection against oxidative stress injury induced by glutamate
  1725. Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats
  1726. Acer okamotoanum protects SH-SY5Y neuronal cells against hydrogen peroxide-induced oxidative stress
  1727. Acetyl cholinesterase inhibition potential and antioxidant activities of ferulic acid isolated from Impatiens bicolor Linn
  1728. Acetylcholinesterase from human erythrocytes membrane: a screen for evaluating the activity of some traditional plant extracts
  1729. Acetylcholinesterase inhibition and antioxidant activities of polysaccharide-peptide complexes from edible mushrooms
  1730. Acetylcholinesterase inhibition and antioxidant activity of Syzygium cumini, S. aromaticum and S. polyanthum from Indonesia
  1731. Acetylcholinesterase inhibition and in vitro and in vivo antioxidant activities of Ganoderma lucidum grown on germinated brown rice
  1732. Acetylcholinesterase inhibition by medicinal plants: A Review
  1733. Acetylcholinesterase Inhibition, Antioxidant, Antiinflammatory, Antimicrobial and Phytochemical Properties of Huernia hystrix
  1734. Acetylcholinesterase inhibitors of natural origin
  1735. Acetylcholinesterase Inhibitory Activity and Antioxidant Activity of Selected Medicinal Plant Extracts Used Against Cognitive Dysfunction and Memory Loss in Sri …
  1736. Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products
  1737. Acetylcholinesterase inhibitory and antioxidant properties of root extract from Pueraria mirifica
  1738. Acetylcholinesterase inhibitory effect of capsicum oleoresins–an in vitro study
  1739. Acetylcholinesterase Inhibitory Potential and Insecticidal Activity of an Endophytic Alternaria sp. from Ricinus communis
  1740. Acetylcholinesterase inhibitory potentiality of some minor fruits of West Bengal, India
  1741. Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family
  1742. Acetylcholineterase inhibitory and antioxidant properties of Rhododendron yedoense var. Poukhanense bark
  1743. Achillea fragrantissima: Pharmacology Review
  1744. Acid Intake, Delivered Via Moderate Champagne Wine Consumption, Improves Spatial Working Memory Via the Modulation of Hippocampal and Cortical …
  1745. Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases
  1746. Activation of anti-oxidant of curcumin pyrazole derivatives through preservation of mitochondria function and Nrf2 signaling pathway
  1747. Activation of Autophagy by Globular Adiponectin Protects against Ethanolinduced Apoptosis in HepG2 Cells
  1748. Activation of Protease-activated Receptor 2 through Gastric Refluxants Stimulates Proliferation and Interleukin (IL)-6, IL-8 and Matrix Metallopeptidase (MMP) …
  1749. Activation of the NRF2 Pathway in Non-adherent Mammosphere Culture System
  1750. Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague‐Dawley rats
  1751. Acute and Chronic Exercise Effects on NrF2 and Antioxidants in the Muscle and Brain Tissue of Sprague Dawley Rats
  1752. Acute Autophagy-Dependent Non-inflammatory Epithelial Death Plays as an Intrinsic Defense to Bacteria
  1753. Acute neurocognitive effects of epigallocatechin gallate (EGCG)
  1754. Add Life to Your Years & Years To Your Life: Experience New Energy, Strength & Vitality to Age Gracefully, Joyfully & Healthily
  1755. Adenosine monophosphate (AMP)-activated protein kinase: a new target for nutraceutical compounds
  1756. Adherence to Mediterranean diet and subjective cognitive function in men
  1757. Adiponectin Modulates Anti-Inflammatory MicroRNA Expression in RAW 264.7 Macrophages
  1758. Administration of chinpi, a component of the herbal medicine ninjin-youei-to, reverses age-induced demyelination
  1759. Advanced chemometric modeling approaches for the design of multitarget drugs against Neurodegenerative diseases
  1760. Advanced Glycation Endproducts (AGEs) in Food: Health Implications and Mitigation Strategies
  1761. Advanced glycation endproducts: what is their relevance to diabetic complications?
  1762. Advances in Date Palm (Phoenix dactylifera L.) Breeding
  1763. Advances in drug discovery to assess cholinergic neurotransmission: a systematic review
  1764. Advances in Nutraceuticals
  1765. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases
  1766. Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein
  1767. Advances in therapeutics for Neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species
  1768. Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors
  1769. Advancing medicine with food and nutrients
  1770. Advancing neuroprotective-based treatments for schizophrenia
  1771. Advocacy in Geriatric Neurology
  1772. Aerobic exercise, diet, and neurocognition among individuals with high blood pressure
  1773. African medicinal plants acting on the reproductive, cardiovascular, and central nervous systems
  1774. Age before beauty
  1775. Age-related deficits in electron transport chain complexes in rat neurons and 3xTg-AD mouse neurons
  1776. Age-related differences in stress response: Increase markers for oxidative stress and liver damage after heat stress in aged rats?
  1777. Age-related epigenetic drift and phenotypic plasticity loss: implications in prevention of age-related human diseases
  1778. Age-Related Neurodegenerative
  1779. Age-related oxidative protein damages in central nervous system of rats: modulatory role of grape seed extract
  1780. Ageing and eating
  1781. Ageing and Neurodegenerative diseases
  1782. Ageing, cellular senescence and Neurodegenerative disease
  1783. Ageing: biology and nutrition
  1784. Ageless Brain: Think Faster, Remember More, and Stay Sharper by Lowering Your Brain Age
  1785. Aging and Microglial Activation in Neurodegenerative Diseases
  1786. Aging and the cerebral microvasculature: clinical implications and potential therapeutic interventions
  1787. Aging is not a disease: implications for intervention
  1788. Aging microglia: relevance to cognition and neural plasticity
  1789. Aging without growing old
  1790. Aging, Nutrition and Taste: Nutrition, Food Science and Culinary Perspectives for Aging Tastefully
  1791. Aging: an important factor for the pathogenesis of Neurodegenerative diseases
  1792. Aging: minimizing free radical damage
  1793. AIMP1 as a Modulator of Immune Functions and Pharmacological Implications
  1794. Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies
  1795. Alcohol, ageing and cognitive function: a nutritional perspective
  1796. Alkaloids from Peumus boldus and their Acetylcholinesterase, Butyrylcholinesterase and Prolyl Oligopeptidase Inhibition Activity
  1797. Allergen-specific memory CD4 T cells require IL-7 signaling for its homeostasis in mediastinal lymph node
  1798. Allergic Asthma Pathogenesis and Antioxidant Therapy
  1799. Almonds and brain functionality
  1800. Alpha-lipoic acid and mesuagenin c-induced co-regulation of nf-κβ-cytokines and chemokines via pi3k-akt/gsk-3β and erk1/2 in in vitro neuronal models/Muhamad …
  1801. Alpha-synuclein suppresses retinoic acid-induced neuronal differentiation by targeting the glycogen synthase kinase-3β/β-catenin signaling pathway
  1802. Alpha-Synuclein-Induced Dysregulation of Neuronal Differentiatio
  1803. Alpha-synuclein, oxidative stress and autophagy failure: dangerous liaisons in dopaminergic neurodegeneration
  1804. Alteration of cholesterol homeostasis in the Huntington’s disease brain
  1805. Altered brain metabolism of iron as a cause of Neurodegenerative diseases?
  1806. Aluminium (III) as a promoter of cellular oxidation
  1807. Aluminum Induced Reproductive Dysfunction in Male Rats: The Ameliorative Effect of Saffron Extract
  1808. Always Eat After 7 PM: The Revolutionary Rule-Breaking Diet That Lets You Enjoy Huge Dinners, Desserts, and Indulgent Snacks—While Burning Fat …
  1809. Amazing Bible Healing Plants, Remedies and Recipes
  1810. Amazing Health Benefits of Green Tea
  1811. Amelioration of oxidative stress in differentiated neuronal cells by rutin regulated by a concentration switch
  1812. Amelioration of scopolamine-induced learning and memory impairment by 𝛼-Pinene in C57BL/6 mice
  1813. Amelioration of the Impact of Physical Fatigue on Cognitive Performance by Phytochemicals: The Effect of a Blackcurrant Supplement: A thesis presented in partial …
  1814. Ameliorative Effects of ferulic acid against lead acetate-induced oxidative stress, mitochondrial dysfunctions and toxicity in prepubertal rat brain
  1815. Ameliorative effects of ferulic Acid against lead acetate-induced oxidative stress, mitochondrial dysfunctions and toxicity in prepubertal rat brain.
  1816. Ameliorative effects of lotus seedpod proanthocyanidins on cognitive deficits and oxidative damage in senescence-accelerated mice
  1817. Ameliorative Effects of Nutraceuticals in Neurological Disorders
  1818. Ameliorative Potential of Euphorbia hirta (Linn.) Extract against Lipopolysaccharide Induced-neuroinflammation and Oxidative Damage in Rats
  1819. Amino acids in human nutrition and health